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ABSTRACT
Epigenetics has been shown to be involved in cellular differentiation, aging and 
disease development. This research project had the objective of verifying whether 
epigenetics, more specifically DNA methylation, plays a role in chondrocyte gene 
regulation during osteoarthritis and cellular differentiation. 
5-azacytidine (5-aza) is a DNA methyltransferase inhibitor that has been used to
treat acute myelogenous leukemia due to its ability to cause global DNA demethylation 
and therefore activation of transcription of tumor suppressor genes that are commonly 
repressed by DNA methylation in this disease. We have used 5-aza to investigate whether 
decreased expression of collagen type II by articular chondrocytes in osteoarthritis could 
be relieved by 5-aza. Chondrocytes were isolated from articular cartilage obtained from 
humans undergoing total joint arthroplasty due to knee osteoarthritis. The cells were 
treated with 5-aza for 4 days and the expression of several chondrocytic genes were 
analyzed by Northern Blot and quantitative PCR analyses. The results showed that 5-aza 
upregulated several chondrocytic genes; however the methylation analyses of the 
collagen type II promoter showed that the collagen type II promoter is highly 
unmethylated. Other mechanisms for the 5-aza effects in articular chondrocytes such as, 
increase in expression of transcriptional activators, decrease expression of transcriptional 
suppressors, increase in expression of growth factors known to modulate the 
chondrocytic phenotype and activation of the DNA damage response with upregulation 
of p21 and p53 were investigated. 5-aza showed to increase the expression of TGF-β3 
and its downstream mediator CTGF; however we did not investigate whether the 
upregulation of these genes were due to demethylation of their regulatory regions. 
Adenoviral over-expression of p53 and p21did not mimic 5-aza effects in articular 
chondrocytes. Nonetheless, the results showed that 5-aza increases the expression of 
extracellular matrix genes critical for cartilage homeostasis in aged- and/or osteoarthritic 
chondrocytes. 
Osteoarthritic chondrocytes undergo phenotypic changes that resemble 
hypertrophic differentiation. Collagen type X is one of the hypertrophic markers that are 
expressed by osteoarthritic chondrocytes. Zimmerman et al. (2008) demonstrated that 
collagen type X expression correlated with demethylation of specific CpGs in the 
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collagen type X promoter by mesenchymal stem cells undergoing chondrogenesis. We 
investigated whether increase in expression of collagen type X by osteoarthritic 
chondrocytes also was due to demethylation of the same specific CpGs. Articular 
cartilage was collected from humans undergoing total joint arthroplasty and categorized 
as normal or osteoarthritic based on its macroscopic appearance. The articular phenotype 
was assessed by expression of collagen type II and aggrecan and the hypertrophic 
markers collagen type X and alkaline phosphatase were also assessed by quantitative 
PCR. The methylation status of the collagen type X gene was analyzed by methylation 
sensitive restriction enzyme digestion followed by PCR. Our results showed that collagen 
type X expression was independent of demethylation of the specific CpG sites and that 
overall the collagen type X promoter is highly demethylated in articular chondrocytes. 
We also have used 5-aza as mean to study the effect of DNA demethylation in 
cellular differentiation in growth plate and articular chondrocytes in horses. 
Chondrocytes were isolated from growth plate and articular cartilage of few days old 
foals, treated or not with 5-aza for 4 days then the cells were divided into 3 groups: 
control (did not receive 5-aza), 5-aza cont (continued to receive 5-aza), 5-aza rec 
(previously treated with 5-aza). These were treated or not with BMP-2 or thyroid 
hormone, agents known to induce chondrocyte differentiation in susceptible 
chondrocytes. The cells were then collected at days 4, 8 and 12 and gene expression of 
the chondrocytic markers collagen type II and aggrecan and the chondrocytic 
differentiation markers was analyzed by Northern Blot analyses and quantitative PCR. 
The results showed that 5-aza variably increase the responsiveness to growth plate 
chondrocytes to BMP-2, however is not able to induce hypertrophic transformation in 
articular chondrocytes.
In conclusion, our results suggest that DNA methylation play a role in 
chondrocyte differentiation and articular cartilage homeostasis. Further studies using high 
throughput technology are warranted to characterize the methylation profile of normal 
articular cartilage, aged cartilage and osteoarthritic cartilage to further understand how 
DNA methylation plays a role during cellular differentiation and disease progression. 
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CHAPTER 1: INTRODUCTION 
There is increasing amount of data indicating that epigenetics play a role in aging 
and aging-related diseases. Of the age-related disease, osteoarthritis is of particular 
importance to current health issues. Osteoarthritis (OA) is a progressive, degenerative 
disease that affects articular cartilage, the synovial lining and adjacent bone of joints. OA 
currently affects over 30% of the US population. This figure is almost certain to increase 
as the American population ages and the childhood obesity “epidemic” impacts the 
consequent development of affected individuals. OA is also an extremely common 
presenting complaint in veterinary patients such as performance horses and several 
popular dog breeds.  
Despite the considerable societal burden associated with OA, current medical and 
surgical therapies for this disease are largely palliative, targeted at controlling the severity 
of clinical signs without affecting disease progression. Consequently, total joint 
replacement is the current “gold standard” for the treatment of OA; a highly invasive and 
costly surgical procedure with its own attendant morbidities and complications. Recently, 
the results of several published studies have linked changes in the chondrocytic 
phenotype that occur during OA to the epigenetic status of chondrocytes. Previous 
research done in the Stewart lab suggests that DNA methylation is involved in the 
regulation of the chondrocytic phenotype. Therefore, the research presented in this 
dissertation is focused on characterizing the effects of DNA methylation on the 
chondrocytic phenotype, identifying the mechanisms by which DNA demethylating 
agents alter the chondrocytic phenotype and defining the role of epigenetics in 
chondrocyte phenotypic stability, control of differentiation and the pathogenesis of OA. 
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The long-term objective of this research program is to develop strategies using epigenetic 
modifying-agents for the prevention or mitigation of OA progression.   
 Briefly, this thesis is composed by a literature review and three data-based 
chapters, presented as manuscripts. The literature review covers the topics of 
osteoarthritis and the different aspects that contribute to disease initiation and 
perpetuation, as well introducing the concepts of epigenetics and what it is currently 
known regarding epigenetic influences on chondrocytes and on osteoarthritis.  
The first study (Chapter 3) addresses the phenotypic effects of 5-azacytidine (5-
aza) in human articular chondrocytes and investigates whether upregulation of collagen 
type II, observed after 5-aza treatment, is associated with demethylation of the promoter 
and enhancer CpG island. In this chapter, we also mapped the methylation status of the 
collagen type II CpG island in cartilage, bone, and several chondrogenic and non-
chondrogenic cell lines. 
The second study (Chapter 4) was prompted by the study of Zimmermann and 
colleagues, published in 2008. This study correlated collagen type X expression during 
stem cell chondrogenesis with demethylation of two specific CpGs in the collagen type X 
promoter. We analyzed whether similar demethylation events occurred in articular 
chondrocytes during osteoarthritis.  
The third study (Chapter 5) investigated the phenotypic effects of 5-aza on equine 
articular and growth plate chondrocytes. More specifically, we studied whether 5-aza 
administration directly stimulated expression of hypertrophic genes in articular and 
growth plate chondrocytes, and whether 5-aza administration affected the phenotypic 
responses of articular and growth plate to hypertrophic stimulation with BMP-2.  
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CHAPTER 2: LITERATURE REVIEW 
 
GENESIS AND PHENOTYPIC CHARACTHERISTICS OF CHONDROCYTE 
POPULATIONS 
 
Chondrogenic differentiation of MSCs and chondrocytic phenotype 
During embryonic skeletogenesis, chondrogenesis is initiated by condensation of 
mesenchymal stem cells (MSCs) derived from somitic or lateral plate mesoderm 1.  
Signals from several morphogens (Transforming growth factor [TGF] -β; Fibroblast 
growth factors [FGF] -2,-4,-8,-10; Bone morphogenetic protein [BMP] -2, -4, -7; Sonic 
Hedgehog [Shh] and  Wnts 3A and 7A), mediated by transcription factors Hox A, Hox D, 
Sox-9, Smads and Gli-3, act in a temporally and spatially regulated manner to drive 
proliferation and condensation of MSCs. During this process, the cells undergoing 
chondrogenesis are characterized by expression of the following extracellular matrix 
proteins: fibronectin, N-cadherin, tenascin, cartilage oligomeric protein (COMP) and 
collagen types I, IIA and XI. The chondroprogenitor cells proliferate and differentiate to 
form a cartilage template, or anlagen, then undergo endochondral ossification to form the 
axial and appendicular skeletal elements.  Chondro-progenitor proliferation is driven by 
insulin growth factor (IGF) -1, FGF-2, BMPs -2, -4, -7, and -14 2. In this phase, the 
transcription factors Sox-9, L-Sox-5 and Sox-6 play key roles, controlling expression of 
several chondrocyte-specific genes such as collagen type IIB (Col II), aggrecan (Agg), 
collagen type XI (Col XI) and link protein (LP) 3-11. Collectively, signaling pathways 
mediated by the secreted ligands parathyroid hormone-related peptide (PTHrP), FGFs, 
4 
 
Indian hedgehog (Ihh), TGF-βs, BMPs, and Wnts interact to control the rate of 
chondrocyte proliferation and hypertrophic differentiation 2, 12-14.  
The hypertrophic stage of differentiation is characterized by expression of 
collagen type X (Col X) and alkaline phosphatase (ALP). Hypertrophic chondrocytes also 
express several matrix metalloproteases (MMPs 2, 3, 9 and 13) and vascular endothelial 
growth factor (VEGF) 15, 16. These factors remodel the hypertrophic cartilage matrix and 
stimulate endothelial progenitor migration, in preparation for vascularization. Terminally, 
hypertrophic chondrocytes undergo apoptosis, and the acellular cartilage matrix is 
colonized by osteoblast precursors that invade the matrix along with vascular endothelial 
elements 12, 14.  
 
Phenotypic similarities and differences between cartilage tissues 
Cartilage is a connective tissue characterized by a small number of cells 
(chondrocytes) interspersed by large amounts of extracellular matrix. Chondrocytes 
engaged in the process of endochondral ossification generate cartilage that forms 
temporary anlagen during skeletal development. Endochondral cartilage persists after 
skeletal development in the growth plates and secondary centers of ossification of 
growing bones and in fracture callus 1, 17, 18. Endochondral cartilage is ultimately replaced 
by bone, although the growth plate cartilages of actively growing long bones persist until 
puberty. In contrast to the transient cartilage at endochondral locations, permanent 
cartilage persists throughout life. Permanent cartilage is found in several anatomical 
locations and is categorized into three types depending on extracellular matrix 
composition. In all locations, cartilage provides solid but deformable structural support. 
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Elastic cartilage is rich in elastin and is found in the ear and epiglottis. Fibrocartilage 
contains collagen type I and it is located in intervertebral discs, menisci, compressive 
regions of tendons and the pubic symphysis. Hyaline cartilage is rich in collagen type II 
and proteoglycans and it is found in the ribs, larynx, trachea, and bronchi, nose and, of 
particular clinical importance, on the articular surfaces of joints.   
Articular cartilage is a highly specialized connective tissue that covers the 
articulating surfaces of bones. It is avascular and rich in extracellular matrix composed 
predominantly of water, collagen type II and proteoglycans. The collagen fibrils provide 
the cartilage with tensile strength and resistance to shear, while aggrecan provides 
resistance to compressive loads 19, 20. Articular chondrocytes do not undergo hypertrophic 
maturation under normal circumstances. Instead, articular chondrocytes persist 
throughout life in a nominally pre-hypertrophic state, characterized by the expression of 
Col II and Agg, with little or no Col X expression or ALP activity 21.  
 
Maintenance of the chondrocytic phenotype in articular cartilage 
 The mechanism by which articular chondrocytes avoid hypertrophy is still not 
completely understood. Several studies indicate that TGF-β signaling is mandatory for 
joint formation and maintenance of articular cartilage. TGF-β receptor II (Tgfbr2) is 
highly expressed in developing joints and lack of Tgfbr2 impairs interphalangeal joint 
development 22. Further, loss of TGF-β signaling results in decreased cartilage synthesis 
and accelerated degradation of proteoglycans, resulting in articular cartilage changes that 
resemble osteoarthritis 23-25.  
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 BMPs, also members of the TGF-β superfamily, also play a role in cartilage 
formation and chondrocyte phenotypic maintenance 1. While single BMP receptor 
knockout mutants (BMP receptor 1A or BMP receptor 1B) form cartilage normally, 
double mutant mice are chondrodysplasic. This indicates that BMP signaling is needed 
for proper chondrogenesis, but some functional receptor redundancy exists in BMP 
signaling 26. BMP signaling is also important for cartilage maintenance, since reduced 
signaling activity leads to cartilage degeneration 27. In vitro, articular chondrocytes 
cultured as monolayers down-regulate endogenous expression of BMP-2 concurrent with 
the loss of the chondrocytic markers Col II and Agg. Addition of exogenous BMP-2 
slows the dedifferentiation process and sustains Col II and Agg expression. Moreover, 
Noggin and a soluble BMP receptor construct, both BMP antagonists, reduced Col II and 
aggrecan expression in aggregate cultures; a culture condition known to maintain the 
chondrocytic phenotype 28. Taken together, these findings confirm that BMP activity is 
also necessary for maintenance of the articular phenotype 29. 
PTHrP is a secreted ligand that plays a role in maintaining chondrocytes in a pre-
hypertrophic state. Weir and others overexpressed PTHrP using a Col II promoter in a 
transgenic model and caused strong inhibition of chondrocyte terminal differentiation in 
growth plates 30. Also, PTHrP-deficient and PTHrP receptor-deficient mice exhibit a 
reduced proliferative stage of differentiation and a concurrent accelerated entry into the 
hypertrophic phase of differentiation31, 32. During endochondral bone formation, PTHrP 
mediates the effects of Ihh on chondrocyte maturation through a negative feedback loop. 
Ihh, secreted by chondrocytes at the transitional boundary between the pre-hypertrophic 
and hypertrophic zones, stimulates the synthesis of PTHrP by periarticular and 
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perichondrial cells at the nascent articular surface. PTHrP diffuses to act on pre-
hypertrophic chondrocytes which express the PTH/PTHrP receptor, to slow the rate of 
differentiation 33, 34. There is evidence that PTHrP’s effects on hypertrophic inhibition are 
partially mediated by inhibition of RUNX-2 activity, a transcription factor mandatorily 
required for chondrocyte hypertrophy 35, 36.  
The role of PTHrP in the maintenance of articular chondrocytes has recently been 
clarified by the Broadus laboratory. This group developed a PTHrP-lacZ knock-in murine 
model which increases the sensitivity of local PTHrP detection by approximately five-
fold. In these mice, PTHrP expression was detected in the proximal growth plate and 
superficial layer of articular cartilage during development. The articular expression 
profile persists after skeletal maturity is reached. They also demonstrated that PTHrP 
expression is load-induced in articular chondrocytes. Mechanical unloading of joints 
decreased the expression of PTHrP and was associated with articular chondrocyte 
hypertrophy 37-39. Given that PTHrP expression was restricted to the superficial zone of 
articular cartilage and this zone is the earliest and most severely affected subpopulation 
of chondrocytes in arthritis, it is highly likely that aberrant PTHrP secretion contributes to 
osteoarthritic progression. However, the extent to which the chondrocyte phenotypic 
changes that occur in osteoarthritis result from decreased PTHrP expression needs to be 
determined.   
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PATHO-PHENOTYPIC ASPECTS OF OSTEOARTHRITIS 
 
Pathogenesis of osteoarthritis 
Osteoarthritis (OA) is the most prevalent age-related disease in the world. There 
are no methods for curing the disease once cartilage degeneration is established and, with 
the exception of total joint arthroplasty, the currently available non-surgical treatments 
are largely palliative. OA affects over 60% of the US population over 65 years of age 40 
and OA-related costs total more than $60 billion per year in the United States economy 
alone 41, 42.  
OA is a non-inflammatory disease characterized by progressive articular cartilage 
degradation 43, calcification 44, and subchondral bone alterations 45. The disease is notable 
for the relative absence of neutrophil and macrophage infiltration, but high levels of 
inflammatory cytokines are produced by synoviocytes and chondrocytes 43, 46, 47, resulting 
in “inflammation-like” cellular responses.  At the cellular level, OA is characterized by 
two phases: an initial biosynthetic phase, during which the chondrocytes increase matrix 
synthesis in efforts to repair damaged cartilage; and a secondary degradative phase, in 
which the enzymes produced by chondrocytes and synoviocytes degrade the cartilage 
matrix and overwhelm any new matrix synthesis 48. Moreover, cartilage degradation 
products derived from the cleavage of fibronectin, collagen type II and matrilins also 
stimulate degradative enzyme secretion, generating a progressive cycle of cartilage 
destruction 49-52. As an example, fibronectin fragment levels are increased in 
osteoarthritic synovial fluid 53and these fragments stimulate metalloproteinase release by 
bovine articular cartilage explants 49.  
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There are two main theories regarding osteoarthritis initiation and progression. 
The first theory emphasizes the consequences of repetitive mechanical injury to articular 
cartilage, while the second theory focuses on chondrocyte senescence 43, 54. The 
“repetitive mechanical injury” model is corroborated by observations that cartilage matrix 
stiffness increases in OA, due to increased collagen cross-linking, with a concomitant 
decrease in compressive resistance due to decreased aggrecan monomer size 55-58. The 
second theory is based on a model where focal proliferation, cumulative oxidative stress 
and mitochondrial dysfunction impair chondrocytes’ capacity to maintain the 
extracellular matrix 54, 59. The role of oxidative stress in osteoarthritis was corroborated 
by large-scale DNA array analyses of human articular cartilage. Seventy-eight human 
cartilage samples were screened using an oligo array covering over 4,000 genes. A 
significant downregulation of anti-oxidative genes such as superoxide dismutases 2 and 3 
and glutathione peroxidase 3 was observed in OA samples 60.  
Besides repetitive mechanical injury and chondrocyte senescence, obesity and 
age-related alterations in the content or consequences of growth factor signaling also 
appear to contribute to the pathogenesis of OA 40, 41, 43, 58, 61. Collectively, the factors 
driving progression of OA lead to a persistent imbalance between the biosynthetic and 
degradative activities in articular cartilage, resulting in irreversible degeneration. 
 
Role of inflammatory cytokines in OA 
Several inflammatory cytokines are up-regulated in OA. These cytokines 
stimulate chondrocytes and synoviocytes to secrete degradative enzymes such as MMPs 
and ADAMTSs (a disintegrin and metalloprotease with thrombospondin motifs) 62-65. 
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MMPs predominantly degrade collagens while ADAMTSs cleave aggrecan. The 
importance of these enzymes in cartilage degradation has been demonstrated in vitro66-69 
and in vivo 68, 70-73. Recent murine models strongly suggest that ADAMTS-5 is the major 
degradative enzyme responsible for cartilage degeneration in OA 68, 74. However, given 
the very different cartilage matrix architecture and biomechanical loading stresses, the 
situation in humans and other higher mammals is likely to be more complex. 
Besides inducing matrix degradative enzymes, cytokines also directly 
downregulate the synthesis of extracellular matrix proteins such as collagen type II 75, 76, 
aggrecan and link protein 41, 77 by articular chondrocytes.  Interleukin (IL)-1β, a major 
inflammatory cytokine in OA, down-regulates collagen type II expression by articular 
chondrocytes by suppressing Sox-9. Sox-9 down-regulation was linked to IL-1β-induced 
expression and phosphorylation of c-Jun, with consequent activation of the AP-1 
transcription factor complex 75.   
IL-6 down-regulates the expression of several cartilage-specific matrix genes, 
such as collagen type II, aggrecan and link protein, by articular chondrocytes 76-78. 
Downregulation of collagen type II is linked to an increase in trans-inhibitory Sp3 
occupancy in the promoter region of the Col II gene 76, 78.  
 
Growth factor activities and dysfunction in OA 
TGF-β signaling is not only significant for maintenance of healthy articular 
cartilage, but also has chondroprotective activities in OA, by counteracting the effects of 
inflammatory cytokines 67, 79-81. TGF-βs stimulate expression of tissue inhibitors of 
metalloproteases (TIMPs), and increase collagen type II and proteoglycan synthesis 82-85 
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by osteoarthritic chondrocytes.  TGF-β2 inhibits the expression of MMP-13 and MMP-9 
by human cartilage explants and consequently decreases collagen type II degradation 81. 
This collagen-protective effect can be attributed to Smad-dependent upregulation of 
TIMP-3, an inhibitor of the major cartilage degradative enzymes MMP-13 and 
ADAMTS-484.  TIMP upregulation by TGF-β1is also effective in the presence of the 
inflammatory cytokine tumor necrosis factor (TNF)-α 67.  
Considering the potential therapeutic benefits of TGF-β activity in OA, clinical 
applications of these activities have not been successful, largely due to the diverse range 
of effects of TGF-β on articular and periarticular tissues. Multiple TGF-β injections in the 
femorotibial joints of mice induced cartilage destruction and osteophyte formation 86. 
This deleterious effect was attributed to TGF-β-induced upregulation of MMP-13, one of 
the major collagenases implicated in osteoarthritis 87. To clarify the role of TGF-β in OA, 
Takahashi and co-workers 80 used genome-wide expression arrays to assess the pathways 
affected by TGF-β and IL-1 treatment in the H4 murine chondrocytic cell line. In this 
experiment, cluster analyses confirmed the protective role of TGF-β by selective 
counteraction of inflammatory/catabolic IL-1-induced genes, but the analyses also 
identified a cluster of genes that may be responsible for the adverse effects induced by 
TGF-β, such as Connective tissue growth factor (CTGF) and VEGF. These factors are 
known to induce cartilage angiogenesis and stimulate MMP production 88, 89, 
exacerbating osteoarthritic pathology.  
 Just as BMPs are critical for normal articular cartilage development and 
maintenance, several BMP ligands have demonstrated chondro-protective effects in the 
context of OA. Osteogenic protein-1 (OP-1), also referred to as BMP-7, confers a 
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protective effect against cartilage degradation in osteoarthritis. OP-1 increases aggrecan 
and collagen type II protein secretion by human articular chondrocytes 90 and restores 
proteoglycan secretion to control levels by articular chondrocytes challenged with IL-191 
or fibronectin fragments 92. OP-1 protective effects were also demonstrated in a rabbit 
model of OA. Joints treated with OP-1 showed less surface fibrillation and cartilage 
deterioration compared to the control group, had significantly greater expression of 
aggrecan and collagen type II, and less aggrecanase expression 93.  Immortalized human 
chondrocyte C-28I2 cells and human primary chondrocytes challenged with IL-1 or 
fibronectin fragments, decreased MMP-13 mRNA and protein expression when treated 
with OP-1 or IGF-1 94. 
 Bmp-2 is also chondro-protective by stimulating extracellular matrix synthesis by 
chondrocytes in vivo and in vitro 29, 95-97. This is corroborated by the fact that mice 
lacking BMP receptor signaling develop cartilage degeneration similar to OA 27. BMP-2 
has shown to modulate collagen type II expression, favoring ‘mature’ collagen type II B 
production over the type II A ‘immature’ variant, by normal and osteoarthritic 
chondrocytes 98. However, BMP-2 also plays a role in chondrocyte hypertrophy and 
osteophyte formation in OA 95, 99, 100. It has been suggested that an imbalance between 
TGF-β and BMP signaling pathways leading to stimulation of Smad1/5 responsive genes 
directs chondrocyte to hypertrophy in OA 21, 101.  
  IGF-1 also has chondro-anabolic activities 102, 103. IGF-1 increases 
glycosaminoglycan content and synthesis and collagen type II expression by equine 
chondrocytes suspended in fibrin 104. In vivo, a composite of chondrocytes and 
polymerized fibrin induced better healing of large full-thickness cartilage defects in 
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horses when IGF-1 was added 105. In addition to increasing the anabolic activity of 
chondrocytes, IGF-1 counteracts the degradative effects caused by cytokine 
administration. TNF-α, IL-1 and oncostatin M stimulated the expression of cartilage 
degradative enzymes MMP-1, -3, -8 and -13,  by human and bovine chondrocytes 67, 106. 
IGF-1 treatment reduced cytokine-induced collagen degradation and antagonized MMP-
1, -3, and -8 upregulation by these cytokines 67, 106.  
There is some evidence suggesting that aging plays a role in the dysregulation of 
growth factor signaling pathway and responses in chondrocytes, leading to cartilage 
degradation and phenotypic alterations 25, 85, 107. As examples, TGF-β2, TGF-β3 and 
TGF-β receptor expression is decreased in old mice 25. Corroborating this finding, TGF-β 
signaling deficiency, through targeted disruption of Smad3 24 or overexpression of a 
truncated, non-functional Tgfbr2 23  leads to articular cartilage changes that resemble 
osteoarthritis.  
Recent evidence indicates that age-related changes in TGF-β/BMP receptor 
expression could contribute to OA initiation and progression 108. TGF-βs conventionally 
signal through Smads 2 and 3, but these ligands are also able to signal though the activin 
receptor-like kinase (ALK) -1 receptor in the absence of more high affinity receptors, 
activating the Smad1/5/8 pathway, which leads to hypertrophic differentiation 85. There is 
an 80% decrease in ALK5 expression in the articular cartilage of aged mice, while ALK1 
expression is relatively unaffected (17% reduction).  Overexpression of AKL1 led to 
phosphorylation of Smad1/5/8 and upregulation of MMP-13; an enzyme secreted by 
hypertrophying growth plate chondrocytes. In addition, downregulation of ALK5 by 
small hairpin (sh) RNA induced MMP-13 expression while ALK1 shRNA abolished 
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MMP-13 expression. Taken together, these data indicate that an increase in ALK1/ALK5 
ratio leads to chondrocyte hypertrophy, activation of MMP-13, and collagen type II 
degradation in OA 108.     
 
Biomechanical influences 
Given that cartilage is a hypocellular tissue (3-5% cellularity) rich in extracellular 
matrix and subject to continuous biomechanical loading, the maintenance of tissue 
architecture and function is heavily dependent on chondrocyte interactions with the 
extracellular matrix (ECM), through cell membrane receptors. These receptors include 
integrins that bind fibronectin and collagens, the discoidin domain receptors (DDR) that 
bind to collagens; CD44, CD62 and intercellular adhesion molecule-1 (ICAM-1) that bind 
hyaluronan 109, 110. Integrins activate major signaling pathways and promote cell adhesion, 
migration, differentiation, proliferation and cell survival 50, 111 and are essential for 
chondrogenesis 112. These receptors also play a role in OA pathogenesis. Cartilage 
degradation products such as collagen, fibronectin and matrilin fragments, stimulate 
degradative enzyme secretion, propagating progressive cartilage destruction 49, 51, 52. 
 Fibronectin-induced upregulation and activation of MMP-13 is activated by α1β5 integrin 
receptor, mediated by the MAP kinase signaling pathway 113, 114.  
DDRs are tyrosine kinase receptors that are activated through interaction with 
collagen 110. More specifically, DDR-2 activation is dependent on interaction with the 
triple helix D2 period of collagen type II and influences adhesion, proliferation and 
extracellular matrix remodeling 110, 115, 116.  Mice with mutations of collagen type IX or XI 
exhibit upregulation of DDR-2 and MMP-13117, 118 and develop osteoarthritis 119, 120. In 
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vitro studies determined that MMP-13 upregulation was dependent on DDR-2 activation 
117, 118, 121. More recently, other groups demonstrated that DDR-2 expression correlated 
with MMP-13 and collagen type II degradation and OA grade in human osteoarthritis, 
using complementary immunohistochemical and quantitative PCR approaches 121, 122. The 
consequent ECM degradation upregulates and activates DDR-2, propagating the cartilage 
destruction observed in OA 121. In addition, DDR-2 also upregulates IL-6 52, an 
inflammatory cytokine that induces MMP expression and inhibits proteoglycan and 
collagen type II deposition 77. 
CD44 is a transmembrane protein that interacts with cytoeskeletal proteins 
allowing for changes in the extracellular matrix environment to be transduced 
intracellularly. It functions as the main hyaluronan receptor and is involved in cellular 
adhesion, migration and differentiation 123, 124. In chondrocytes, CD44 is responsible for 
attachment of hyaluronan-proteoglycan aggregates to chondrocytes’ surface and needed 
for maintenance of cartilage homeostasis 125-127. The importance of CD44 expression and 
extracellular homeostasis was demonstrated by siRNA inhibition. Chondrocytes and 
cartilage treated with CD44 antisense oligonucleotides showed depletion of extracellular 
proteoglycan similar to osteoarthritis 127. Moreover, in chondrocytes, CD44 has been 
shown to be involved in internalization and turnover of hyaluronan and G1 aggrecan 
domain 128, 129 and signal transduction 130, 131.Therefore, the ability to repair cartilage 
damage is not only dependent on upregulation of matrix extracellular genes but also in the 
capability to incorporate those proteins to the extracellular matrix to re-establish the 
pericellular environment 125, 126.  In osteoarthritis, the massive accumulation of hyaluronan 
and G1 aggrecan fragments due to extracellular matrix degradation may overcome CD44 
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turnovers capability. This may lead to lack of binding sites to newly formed hyaluronan 
and proteoglycans impeding cartilage repair 132.  
  
Subchondral bone alteration and cartilage calcification 
 Subchondral bone alteration is a major pathological characteristic of arthritis. The 
extent to which these alterations influence osteoarthritic progression is not well defined. 
Clearly, subchondral bone sclerosis will alter the biomechanical loading experienced by 
the adjacent articular cartilage. However, there is also evidence supporting direct effects 
of subchondral osteoblasts on articular chondrocyte activities. Human chondrocytes 
suspended in alginate beads were co-cultured with osteoblast monolayer cultures, isolated 
from sclerotic or non-sclerotic bone. Sclerotic osteoblasts inhibited aggrecan gene 
expression and protein secretion and also increased MMP-3 and -13 gene expression by 
chondrocytes. Similar results were obtained when non-sclerotic osteoblasts were pre-
incubated with inflammatory cytokines (IL-1β, IL-6 or oncostatin M (OSM)) prior to co-
culture 133.  In another study, sclerotic osteoblasts decreased expression of collagen type 
II, Sox-9, PTHrP and its receptor (PTH-R) and increased expression of osteoblast 
stimulating factor 1 (OSF-1) by articular chondrocytes 45. Taken together, signals from 
osteoblasts in the sclerotic subchondral bone compartment could contribute to cartilage 
degradation and phenotypic shift of articular chondrocytes in OA.  
 
Patho-phenotypic characteristics of OA chondrocytes 
Although OA is predominantly characterized by loss of ECM homeostasis, the 
disease also causes distinct phenotypic alterations in the resident chondrocyte population. 
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These phenotypic changes resemble the transitions that occur during hypertrophic 
differentiation of endochondral lineage chondrocytes 134. Articular chondrocytes down-
regulate Col II and Agg expression 48, 135 and begin to express Col X 21, 136-139. This has 
been demonstrated by microarray comparisons 140 and differential Col X immunostaining 
in OA and normal cartilage 138, 141. Aberrant expression of other hypertrophic markers 
such as ALP and osteocalcin (OCN) have also been linked to OA 141, 142. Osteocalcin 
mRNA and protein expression were increased in the subchondral bone plate from patients 
with severe OA and was also present in OA chondrocytes in the deep cartilage layer and 
in chondrocyte clusters 141. Late stage OA samples also were positive for Col X and ALP 
expression, which reinforces the hypertrophic-like phenotypic change that occurs in 
osteoarthritis chondrocytes.  
Articular chondrocytes also upregulate expression of MMPs that are 
physiologically expressed, by hypertrophic chondrocytes, during the final stage of 
hypertrophic differentiation 15, 16. In endochondral cartilage, MMPs act to remodel 
hypertrophic cartilage in preparation for vascularization and matrix mineralization. In 
articular cartilage, increased MMP activity results in cleavage of critical ECM proteins 
and consequent tissue compromise. Therefore, dysregulation of mechanisms involved in 
chondrocyte differentiation and phenotypic stability are directly implicated in the 
pathogenesis of OA. 
Mineralization of cartilage is a recognized pathological alteration in OA. Fuerst 
and co-workers analyzed the excised cartilage specimens from humans undergoing total 
joint replacement. All one hundred and twenty specimens showed mineralization of 
cartilage that correlated with Col X expression and chondrocyte hypertrophy. The 
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secreted minerals were identified as basic calcium phosphates; the same crystals known 
to be produced by hypertrophic chondrocytes during endochondral ossification 44. The 
close relationship between ALP activity, matrix vesicle formation and cartilage 
mineralization in osteoarthritic cartilage, was demonstrated using electron microscopy 
142. The increase in number of apoptotic cells in osteoarthritic cartilage has also been 
linked to cartilage calcification 143.   
The mechanisms that drive articular chondrocyte phenotypic destabilization in 
OA are largely unknown. Age-related changes in TGF-β and BMP signaling pathways 
and activities are obvious candidates that could contribute to osteoarthritis pathogenesis 
40, 41, 43, 58, 61, 108.  In addition, the recent findings that PTHrP are expressed by murine 
articular cartilage subpopulations after skeletal maturity was reached 37, 39, suggest that 
loss of PTHrP expression by articular chondrocytes, is a key event facilitating 
chondrocyte hypertrophy during OA.   
Ihh is a secreted ligand involved in skeletogenesis and chondrocyte 
differentiation. Since Ihh is linked to PTHrP activities in endochondral chondrocytes, the 
participation of Ihh in the pathogenesis of OA has been addressed. Lin and co-workers 
used several transgenic mouse models to demonstrate that activation of hedgehog 
signaling leads to upregulation of genes known to be increased in OA such as ADAMTS-
5, COL10A1, RUNX-2 and MMP-13, along with radiographic and histologic changes 
characteristic of OA 144. Accepting these findings, the mechanism(s) by which Ihh could 
be upregulated in OA cartilage has not yet been identified.  
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EPIGENETIC INFLUENCES ON CELL DIFFERENTIATION AND 
PHENOTYPE 
 
Epigenetics refers to “mechanisms that initiate and maintain patterns of gene 
expression and gene function in a heritable manner without changing the sequence of the 
genome” 145. Epigenetics impact gene regulation though DNA methylation, histone 
protein modifications and chromatin organization. Overall, DNA methylation of CpG 
islands is associated with histone hypoacetylation that collectively repress transcription. 
DNA methyltransferases methylate cytidines at CpG dinucleotide sites. This modification 
can interfere with the recognition and attachment of DNA binding proteins to genomic 
cis regulatory elements. Additionally, methyl-CpG binding proteins are recruited to 
methylated CpGs (mCpG) and, in turn, recruit histone deacetylases (HDACs), histone 
methyltransferases (HMTs) and chromatin-remodeling factors to methylated regions. 
These modifications condense chromatin structure, sequestering potential binding sites 
from transcriptional activators and restricting occupancy 146. However, promoter 
occupancy does not depend solely in its epigenetic state. Transcription activation and 
repression are also regulated by competitive binding of promoter, enhancer and silencer 
elements 76, 78, 147-150. Therefore, activation or repression of a gene is a collective 
consequence of the interplay of transcription factors and epigenetic constraints.   
Epigenetic processes are involved in regulation of germline-specific genes, tissue-
specific genes, imprinting, and aging 151-155. A growing body of work indicates that 
epigenetics is also critical in a range of disease processes. For instance, the hallmark of 
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neoplastic cells is global DNA hypomethylation and hypermethylation of specific tumor 
suppressor genes which are transcriptionally suppressed 156. 
 
Histone modifications 
Histones are nuclear proteins involved in DNA packaging through chromatin 
formation. A nucleosome is a chromatin unit formed by a core of histones (two H2A-
H2B dimmers and a H3-H4 tetramer) and 147 base pairs of DNA wrapped around an 
octamer of histones. Modification of the histone amino-tails, in conjunction with other 
nuclear proteins, link histones and DNA methylation play a role regulating chromatin 
structure and gene accessibility157, 158.   
Histone acetyltransferases (HATs) are responsible for the acetylation of specific 
lysine residues in the histone amino-tails. The GNAT, MYST, p300/CBP, SRC and 
TAFII250 families are known to be able to catalyze the transfer of acetyl residues to 
histone amino-tails, facilitating transcriptional activity 159. On the other hand, histone 
hypoacetylation correlates with gene repression. Heterochromatin, for example, is 
characterized by histone (H) 3 lysine (K) 9 methylation, H4 hypoacetylation, CpG 
methylation and presence of the heterochromatin protein HP1. Methylated H3K9 and the 
DNA methyltransferases (Dnmts) serve as binding sites for heterochromatin (HP) -1 and 
methyl binding proteins (MBPs) 160. MPBs recruit histone deacetylases (HDACs) and 
chromatin-remodeling proteins, leading to deacetylation of histone amino-tails, chromatin 
compaction and repression of gene expression 161, 162. While methylated H3K9 is located 
mainly in pericentromeric heterochromatin, H3K27 trimethylation correlates with 
silencing of homeotic genes and also is found in the inactive X chromosome 163. H3K27 
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trimethylation is carried out by the Polycomb methyltransferase EZH2 164 that has been 
shown to associate with Dnmts, and to be necessary to establish DNA methylation and 
silencing of genes involved in development. On the other hand, activation of transcription 
of genes involved in development is mediated by the Trithorax complex which is 
associated with H3K4 trimethylation 165-168.  
Genome-wide screening has also defined a range of histone marks that correlate 
with functional activities of genomic sequences such as transcript-coding sequences223, 
exon boundaries227, active enhancers221, telomeric and long-terminal repeat sequences223. 
It is apparent that histone modifications, in conjunction with the transcriptional 
machinery comprised of RNA polymerase and associated transcription factors, 
collectively delineate the transcriptional state of the genome.   
 
DNA methylation 
DNA methylation is a post-replication modification catalyzed by DNA 
methyltransferases. In mammals, the Dnmts catalyze the transfer of a methyl group from 
S-adenosyl-methionine to the carbon 5 of cytosine in the CpG dinucleotides. Cytosine 
methylation in CHG and CHH sites (where H= A, T or C) is found in embryonic stem 
cells and disappear after differentiation 169. Other forms of DNA methylation found in 
humans are methylcytosines and hydroxymethylcytosines 170, but their significance still 
remains unknown.  To date, five Dnmts have been identified: Dnmt1, Dnmt2, Dnmt3A, 
Dnmt3B and Dnmt3L. However, only Dnmt1, 3A and 3B have methyltransferase activity 
in vivo. Dnmt2 has very little methyltransferase activity in vitro 171. More recently, its 
methyltransferase activity was reported to regulate retrotransposon silencing and 
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telomere integrity in Drosophila melanogaster 172 and to methylate tRNA 173.  Dnmt3L 
lacks the methyltransferase catalytic domain but contributes to de novo methylation by 
interacting with the catalytic domains of Dnmt3A and Dnmt3B, enhancing their 
enzymatic activity 174, 175.  Considering that Dnmts1, 3A and 3B may have some 
overlapping function 176, Dnmt1 primarily functions to maintain the genomic methylation 
status following replication. By interacting with proliferating cell nuclear antigen 
(PCNA), Dnmt1 detects hemi-methylated sites during replication and methylates the 
newly replicated DNA strand 177. In contrast, Dnmt3A and 3B are primarily responsible 
for de novo DNA methylation 178. All these methyltransferases are critical for 
embryogenesis, since deletions of any DNA methyltransferase (Dnmt1, Dnmt3A or 
Dnmt3B) result in embryonic lethal phenotypes 179. 
CpG dinucleotides present a bimodal distribution in the genome, reflecting an 
evolutionary feature.  Most of the genome is CpG-poor due to cumulative deamination of 
methylated cytidines to thymidines, which generates a TpG mutation after replication. 
However, deamination of non-methylated cytidines forms uridines which are easily 
detected by the excision repair system and therefore persist as CpGs in the genome 171. 
There are specific areas in the genome that hold a greater concentration of CpG 
dinucleotides than expected, based on ‘background’ incidence. These regions are termed 
‘CpG islands’ and correlate with promoter sequences of housekeeping genes and 
approximately 40% of tissue-specific genes 180, 181. Takai and Jones (2002) defined CpG 
islands as regions longer than 500bp, containing more than 55% CGs and an observed 
CpG/expected CpG ratio of 0.65 182. CpG islands localized in promoter regions are 
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usually unmethylated in normal tissues, regardless of the transcriptional activity of the 
gene 183. 
DNA methylation can repress transcription through transcription factor binding 
exclusion 184, 185. As an example, CpG methylation is known to interfere with CTCF 
binding and regulate expression of H19/Igf2 imprinted genes.  CTCF is an insulator that 
binds DNA when its consensus sequence is unmethylated.  In such cases, CTCF binds to 
a region between the gene promoter and enhancer, silencing the maternal copy of the Igf2 
gene. On the other hand, when the CTCF binding site is methylated, CTCF is unable to 
bind and the paternal copy of the Igf2 gene is expressed 186, 187.  
Methylated CpGs are also recognized by proteins that have a methyl-binding 
domain (MBD). To date, several methyl-binding proteins have been identified: MeCP2 
188, MBPs 1-4 and Kaiso 189. Recently, Ho and colleagues demonstrated that MeCP2 
contacts the water molecule tightly bound to the major groove of methylated DNA rather 
than methylated cytosine itself 190. Methyl-binding proteins interact with histone 
deacetylases, histone methyltransferases (HMTs) and chromatin-remodeling complexes, 
resulting in chromatin compaction and gene silencing 161.  
Several epigenetic marks have been linked to gene silencing though the formation 
of heterochromatin. However, the sequence of mark acquisition and the relative 
importance of specific genomic alterations are somewhat controversial. The importance 
of CpG methylation is emphasized by the observation that methylated transgenes bind 
methyl-CpG-binding proteins that recruit HDACs and result in silencing 191-193. Fuks and 
co-workers showed that MeCP2 associates with histone methyltransferases at H3K9, 
linking DNA methylation to consequent chromatin modifications that reinforce gene 
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silencing 194. In contrast, findings in Neurospora crassa and Arabidopsis thaliana, 
suggest that DNA methylation is a secondary event that follows gene silencing by histone 
modifications. For instance, the histone methyltransferase, dim-5, is necessary for DNA 
methylation in N. crassa 195. Similarly, when kryptonite, a HMT, is mutated in A. 
thaliana, major loss of DNA methylation occurs, leading to reactivation of transcription 
of several normally silenced genes 196, 197.  In mammals, DNMT1 and 3A were shown to 
be associated with SUV39H1 (a HMT that methylates H3K9) 160. This suggests that 
DNMTs could be recruited to sites marked by H3K9 methylation through interaction with 
SUV39H1, and that histone methylation would therefore be required for DNA 
methylation.  On the other hand, Mustkov and co-workers showed that a transgenic 
cassette stably integrated in chicken erythroid cells was inactivated primarily by 
hypoacetylation of H3 and H4 and loss of methylation at H3 lysine 4 198. In this system, 
histone H3 K9 and promoter DNA methylation were secondary events and histone and 
DNA methylation occurred at the same time 198. Taken together, the current data indicate 
that gene silencing involves coordinated and complementary DNA modification and 
protein complex interactions to achieve transient or permanent gene silencing. 
 
MicroRNAs 
MicroRNAs (miRNAs) are ~ 22 nucleotide long, non-coding RNA molecules 
involved in posttranscriptional regulation of gene expression. They are transcribed by 
RNA polymerase II, processed in the nucleus by the RNase III Drosha and DGCR8 into 
precursor miRNAs, exported to the cytoplasm by Exportin-5 and finally processed by the 
RNase III Dicer into mature miRNAs. In the cytoplasm, miRNAs associate with RNA-
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induced silencing complex (RISC) and target mRNA transcripts to degradation or 
suppress their translation 199-201.  
There are several types of non-coding RNA. Some are involved in epigenetic 
regulation such as X inactivation, dosage compensation, imprinting, and Polycomb 
silencing. Because microRNAs are closely associated with small interfering RNA, and 
the latter has been associated with DNA methylation and histone modifications, 
microRNAs have been considered to be “epigenetic” factors 200, 202, 203. In addition, 
microRNAs are involved in DNA methylation in Arabidopsis thaliana 204 and might be 
involved in regulating the histone deacetylase HDAC4 in murine developing cartilage 205. 
At this stage, however, the epigenetic role of microRNA is predominantly indirect. 
There is a rapidly growing body of evidence that microRNAs play a role in gene 
regulation during development, cellular differentiation, aging and immunity 201, 206-212. 
Also, microRNAs are implicated in oncogenesis; and in the age-related diseases 
Parkinson’s disease and Alzheimer’s disease; and rheumatoid arthritis 201, 212-214. More 
recently, miR-155 and miR-146 were identified in synovium from RA and OA patients 
215-217. miR-146 is upregulated by TNF-α and IL-1β but its function remains unknown. 
miR-155 is upregulated by cytokines and Toll-like receptor ligands, and it might work 
modulating MMP response by RA synovial fibroblasts 215, 216. 
 
The epigenomic landscape 
The recent development of high throughput technologies (ChIP-chip and ChIP 
sequencing) 170, 218 have allowed researchers to identify and map epigenetic marks across 
the entire genome, to compare epigenetic features of specific regions between different 
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tissues, and to associate epigenetic alterations with gene transcriptional states. Analyses 
of several human tissues, placenta, sperm, mouse embryonic stem cells, neural progenitor 
cells, embryonic fibroblasts and several cell lines in addition to cells in different stages of 
differentiation,  led to identification of certain epigenetic features:  
1- in general, promoter methylation correlates negatively with gene expression at high-, 
medium- and low-CpG density promoters;  
2- promoter hypomethylation and gene body methylation positively correlates with gene 
expression;  
3- promoters with few CpGs can be active and methylated;  
4- exons are more highly methylated than introns, and sharp transitions occur at exon–
intron boundaries, suggesting that differential methylation is involved in splicing;  
5- about 25% of methylation found in embryonic stem cells is not in a CpG context and is 
lost during cellular differentiation;  
6- while overall methylation decreases, developmentally regulated and pluripotency-
associated genes become methylated during stem cell differentiation; 
7- methylation of CpG island shores (regions of lower CpG density near (~2 kb) CpG 
islands) of promoter-associated CpG islands correlates with transcriptional 
inactivation;  
8- most tissue-specific DNA methylation is found in CpG island shores, not at CpG 
islands;  
9- unmethylated promoters are associated with H3K4 trimethylation and are actively 
transcribed; 
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10- H3K4 trimethylation, H3K4 dimethylation, and H3 acetylation are localized to the 
transcriptional start sites of genes;  
11- H3K27me3 is associated with inactive promoters; 
12- “bivalent domains” (H3K4me3 active mark found together with the H3K27me3 
repressive mark) are present at promoters of developmentally important genes in 
embryonic stem cells and are lost during cell differentiation;  
13- H3K9 and H3K27 trimethylation are usually associated with heterochromatin 
formation and silencing of transcription through the Polycomb group proteins;   
14- H3K9 trimethylation and H3K20 trimethylation are found at satellite, telomeric and 
active long-terminal repeats;  
15- active enhancers are marked by H3K4 monomethylation and H3K27acetylation;  
16- H3K36 trimethylation marks exons; 
17- cell line epigenetic profiles do not correspond to the epigenetic profiles of their 
primary tissue; 169, 219-229 
It is becoming increasingly evident that multiple epigenetic alterations function in 
concert with RNA polymerase and associated core transcription factors to regulate 
transcriptional activity across the genome. 
 
DNA methylation, cellular differentiation and phenotypic stability  
 Several studies have demonstrated the importance of epigenetics in stem cell 
differentiation and lineage commitment. For example, several germline-specific genes are 
methylated in fibroblasts but not in sperm 230, suggesting that DNA methylation is 
involved in repression of germ-line specific genes in somatic cells, and participates in the 
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epigenetic regulation of gene expression during cell differentiation 231-233. Moreover, 
genome-wide screens have provided information on differential methylation in different 
types of tissues 232, 234-237. The largest study in this field was published in 2008 by Rakyan 
and colleagues 224. They used Methylated DNA Immunoprecipitation (MeDIP) associated 
with microarrays to investigate the methylation and gene expression profile of 13 normal 
somatic tissues, placenta, sperm and a lymphoblastic cell line. They identified several 
differentially methylated regions (tDMRs) which regulate tissue-specific gene 
expression.  
 
DNA methyltransferase inhibitors 
The DNA methyltransferase inhibitors are derivates of 5-azacytidine (5-aza). 5-
aza is a cytidine analog modified at position 5 that cannot be methylated. It was originally 
synthesized by Piskala and Sorm in 1964 with the objective to treat acute myelogenous 
leukemia 238.  Nowadays, 5-aza and several other cytidine analogues, such as 5-aza-2-
deoxicytidine (5-aza-CdR), zebularine, and decitabine, among others, are used to treat 
several neoplastic diseases 183, 239.  
5-aza has its effect on genomic methylation by functioning as a cytidine analog 
during DNA replication. Generally, only 5% of cytidines are substituted by 5-aza, but this 
degree of substitution is sufficient to induce a global decrease in genomic DNA 
methylation (80-85%), since incorporated 5-aza covalently binds Dnmt1 240-243. This 
effectively sequesters the enzyme and leads to a global reduction in genomic methylation 
242, 243.  
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There are other mechanisms by which 5-aza might influence chondrocyte activity. 
DNA/Dnmt adducts triggers a DNA damage response which leads to p53 activation, 
increased p21Waf1/Cip1 expression, and cell cycle inhibition 244. Zhu et al, 2004 245used 
deletion analyses and site-directed mutagenesis of the p21 promoter to demonstrate that 
5-aza-CdR induction of p21Waf1/Cip1 expression requires two p53 binding sites in the 
p21 promoter. Comet assays and bisulfite sequencing were used to demonstrate that 5-
aza-CdR-induced p21Waf1/ Cip1 expression was dependent on DNA damage but not on 
DNA demethylation. 
Others have also demonstrated that 5-aza-CdR has replication-independent effects 
246-249. Firstly, 5-aza-CdR is able to induce Dnmt1 degradation by the proteosomal 
pathway 249. Secondly, Dnmt1 can control DNA methylation in a replication-independent 
manner since it binds chromatin throughout G2 and M phases 248. Finally, 5-aza can be 
incorporated into RNA, resulting in the inhibition of RNA and protein synthesis 
independently of any effect on the genome 246, 247.  
 Therefore, 5-aza and its analogs can influence cellular systems through their 
ability to decrease global methylation in replication-dependent or –independent manners, 
through DNA damage response, or through inhibition of mRNA and protein synthesis. 
These alternative mechanisms are particularly pertinent to the actions of 5-aza in 
chondrocyte populations, since phenotypically stable chondrocyte culture models (low/no 
serum-suspension/non-adherent) do not support sustained cell proliferation. 
DNA methyltransferase inhibitors have been used to experimentally address the 
effects of DNA methylation on cellular differentiation and phenotypic stability. For 
instance, DNA methyltransferase inhibitors induce mouse embryo fibroblasts to 
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differentiate into muscle, adipose tissue and chondrocytes 250-252. In addition, 5-aza-CdR 
prevents differentiation of spermatogonia into spermatocytes in mouse 253, which 
suggests that DNA methylation is important for terminal differentiation of spermatocytes. 
In contrast, the treatment of articular chondrocytes with DNA methyltransferase inhibitor 
alleviates molecular constraints that prevent these cells from achieving terminal 
maturation 254.  
 
EPIGENETICS AND CHONDROCYTE PATHOBIOLOGY 
 
Epigenetics and aging 
During aging there is a change in methylation pattern leading to methylation of 
CpG islands and global demethylation of the genome. Methylation of CpG islands is 
associated with suppression of tumor suppressor genes and oncogenesis 200, 255. In 
addition, histone deacetylase activity is decreased in aged tissues and it seems to have an 
important role increasing lifespan, as demonstrated in yeast and mice 256. Moreover, 
H4K20 trimethylation, a repressive marker, has also been shown to be increased in aging 
257. MicroRNAs have also been implicated in age-related diseases, ie Parkinson’s disease 
and Alzheimer’s disease 214. Therefore, it seems that alterations in the epigenetic status 
during aging, leads to redistribution of heterochromatin, changes in pattern of gene 
expression, increases genomic instability and impairs cell function. 
Several age-related diseases, such as atherosclerosis, neurologic disorders, cancer, 
and autoimmune diseases, have been linked to altered cell function due to epigenetic 
alterations 258.  Moreover, cells obtained from elderly people present epigenetic 
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alterations similar to those observed in Progeria, a syndrome characterized by an 
accelerated aging phenotype 257. This suggests that epigenetics influence the process of 
aging itself.   
Some studies suggest that certain changes during OA might be related to 
epigenetic changes in gene regulation 61, 259, 260. The extent to which epigenetics play a 
role in OA, and the extent to which these changes are related to epigenetic changes due to 
senescence, remains unknown.  
 
Epigenetics and rheumatoid arthritis   
Rheumatoid arthritis (RA) is an auto-immune disease characterized by chronic 
inflammation of several joints, synovial hyperplasia and cartilage destruction. 261. MMP-
1, a cartilage degradative enzyme, is increased in RA synovial fibroblasts (RASFs). 
Maciejewska-Rodrigues and colleagues demonstrated that epigenetics play a role in the 
regulation of MMP-1 expression in RA. The MMP-1 promoter is hyperacetylated in 
RASFs compared to OA synovium fibroblasts; and transcriptional repression depends on 
HDAC4 262. Further, global HDAC activity was decreased in synovium from RA patients 
when compared to synovium from OA patients 263. In addition, RASFs show global 
hypomethylation of the genome when compared to OA synovial fibroblasts 264, 265. 
Activation of LINE-1 (long interspersed nuclear element-1) retrotransposons by 
hypomethylation might be involved the pathogenesis of the activated phenotype of 
RASFs. Normal synovial fibroblasts treated with the Dnmt inhibitor 5-aza-CdR changed 
their cellular profile into an RASF-like phenotype 264.  
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MicroRNAs also appear to be involved in RA pathogenesis. miR-155 and miR-
146 are present in higher amounts in RA synovium than in OA or normal synovium and 
are upregulated by TNF-α and IL-1β treatments 215, 216. RA synovial fibroblasts treated 
with TNF-α, IL-1β, lipopolysaccharide or bacterial lipoprotein upregulated miR-155 and 
miR-146. miR-155 decreased MMP-3 expression and reduced the induction of MMP-3 
and MMP-1 by TNF-α, IL-1β, lipopolysaccharide or bacterial lipoprotein 216.  This 
suggests that microRNAs might be involved in the modulation of inflammatory response 
by RASFs in rheumatoid arthritis.    
 
Epigenetics and chondrocyte biology 
Several recent studies have demonstrated the importance of epigenetic gene 
regulation in chondrocyte development and homeostasis.  
Sox-9 is a transcription factor master regulator of several chondro-specific genes 
3-11. Tsuda and co-workers demonstrated that histone acetyltransferase, CBP/p300, 
associates with Sox-9 to regulate transcription of the Col II gene in chondrocytes 266. 
CBP, p300 and Sox-9 were overexpressed in the chondrosarcoma cell line SW1353, 
resulting in increased Col2a1 promoter activity. Co-immunoprecipitation and Western 
Blot analyses showed that Sox-9 interacts with HA-CBP or HA-p300. Moreover, 
chromatin immunoprecipitation demonstrated that p300 binds to the collagen type II 
promoter region. Disruption of the CBP/Sox9 interaction inhibited MSC chondrogenesis 
266.  Taken together, these findings demonstrate that the CBP/p300 are co-activators of 
Sox9 in the regulation of chondro-specific genes and during in vitro chondrogenesis.   
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Furumatsu and colleagues, also from the Asahara lab, investigated the 
mechanisms by which p300 acts as Sox-9 co-activator. Chromatinized DNA templates 
were used to assess Sox-9 dependent expression in vitro. p300 increased Sox-9 dependent 
transcription on chromatin and correlated with hyperacetylated histones. Moreover, 
trichostatin A, a histone deacetylase inhibitor, stimulated expression of Col II and 
aggrecan, and increased nucleosomal acetylation around the Sox-9 binding site in 
chondrocytes 267. These results support a model whereby the gene-specific factor Sox-9 
interacts with chromatin-remodeling factors to activate Col II transcription. This model 
likely represents a more general trans-regulatory mechanism by which tissue-specific 
transcription factors recruit non-specific chromatin-modifying agents to lineage-
associated genes.  
HDAC4 is a class II histone deacetylase and is specifically involved in regulation 
of chondrocyte hypertrophy. HDAC4 null mice exhibit a premature chondrocyte 
hypertrophy and ossification phenotype, characteristics similar to mice that overexpress 
RUNX-2 in chondrocytes. Corroborating this association, constitutive expression of 
HDAC4 mimics the phenotype seen in RUNX-2 knockout mice 268. In vitro studies 
showed that HDAC4 interacts with Runx2, inhibits Runx2 DNA binding and decreases 
histone acetylation of RUNX-2 promoter 268.  HDAC4 also interacts with and represses 
the transcription factor MEF2 (myocyte enhancer factor 2) that is also required for 
chondrocyte hypertrophy. PTHrP mediates the dephosphorylation and consequent nuclear 
localization of HDAC4 in pre-hypertrophic chondrocytes, facilitating MEF2 repression 
by HDAC4 269. Over-expressed HDAC4 had similar hypertrophy-inhibitory effects in a 
chondrogenesis model utilizing synovial derived MSCs 270.These findings indicate that 
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HDAC4 functions as a negative regulator of chondrocyte hypertrophic differentiation by 
suppressing the activities of Runx2 and MEF2, a transcription factors required for 
hypertrophy. The extent to which HDAC4 affects this regulation through histone 
modifications, as opposed to altering the acetylation status of non-histone substrates, has 
not yet been clarified. 
Experimental evidence exists that indicates HDAC activity is also necessary to 
support collagen type II expression in articular chondrocytes, and permit re-
differentiation of (monolayer) de-differentiated chondrocytes 271. In this study, HDAC 
inhibitors trichostatin A (TSA) and PXD101 inhibited collagen type II expression by 
articular chondrocytes and prevented re-differentiation of dedifferentiated chondrocytes. 
Knockdown studies supported the conclusion that HDACs inhibit collagen type II 
expression by upregulating Wnt-5A, a signaling protein known to suppress the 
chondrocytic phenotype. In addition, chromatin immunoprecipitation showed an increase 
in histone acetylation of the Wnt-5A promoter in the presence of HDAC inhibitors 271.  
DNA methylation also plays a role in regulating the chondrocytic phenotype. 
Phenotypically stable, chick articular chondrocytes, cultured as monolayers and treated 
with the DNA methyltransferase inhibitor, 5-aza, undergo hypertrophy, expressing Col X, 
Ihh, and ALP 254. Bmp-2 treatment increased Col X and ALP expression by chondrocytes 
treated with 5-aza. On the other hand, Tgf-β and PTHrP treatment reduced Col X 
expression. To investigate the mechanisms involved in chondrocyte hypertrophy 
following 5-aza treatment, expression of the BMP Smads (1 and 5), the TGF-β Smads (2 
and 3), and the Smad2/3-degrading ubiquitin E3 ligase Smurf2 were assessed by Western 
Blot analyses. 5-aza treated chondrocytes had increased levels of Smad1, 5, and Smurf2 
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and decreased levels of Smad2 and 3 proteins. Smurf2-dependent degradation of Smad2 
and 3 was demonstrated by pulse-chase experiments to measure ubiquitination and half 
life 254. Altogether, the data suggest that differential DNA methylation is involved in the 
regulation of TGF-β and BMP signaling interactions to control lineage commitment of 
chondrocyte populations. Accepting this, no data were presented in this study that 
demonstrated a direct link between altered methylation states and consequent phenotypic 
alterations.  
In a related study, fetal bovine chondrocytes cultured as monolayers responded to 
5-aza treatment in a similar manner, expressing hypertrophic markers.  Cells exposed to 
5-aza for 48 hours decreased collagen type II expression and up-regulated hypertrophic 
markers such as ALP and Col X 272. These cells also increased expression of PTHrP and 
the PTHrP receptor. These genes are markers of pre-hypertrophic chondrocytes, and are 
not expressed by hypertrophic cells. It is likely that the observed changes in gene 
expression in this study reflect a range of phenotypic states in the sample population, 
rather than a consistent and uniform response to 5-aza.  In addition, human articular 
chondrocytes cultured in alginate beads undergo phenotypic changes that resemble 
hypertrophy, following 5-aza treatment, with modest increases in Col X and ALP 
expression and down-regulation of collagen type II expression.  Chondrocyte size and 
apoptosis were also increased following 5-aza exposure. The authors suggested that this 
model could be applied to study the cellular mechanisms of OA 273.  
It is worth mentioning that there were no attempts to ensure that 5-aza worked as 
a demethylating agent in the experiments above described. 5-aza also induces cellular 
responses through the DNA damage response, which leads to p53 activation, 
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p21Waf1/Cip1 up-regulation and cell cycle arrest 245. This mechanism can explain the 
increased chondrocyte apoptosis observed in Ho’s study, for instance. It is a distinct 
possibility that other non-epigenetic mechanisms might be involved in the 5-aza mediated 
phenotypic shifts described above.  
 
Epigenetics and osteoarthritis 
HDAC inhibitors have been investigated as potential therapeutic agents for the 
treatment of osteoarthritis 274. Young et al. (2005) utilized a bovine nasal cartilage 
explant model to induce cartilage matrix degradation by a combination of IL-1α and 
oncostatin M. Explants co-treated with HDAC inhibitors (trichostatin A or sodium 
butyrate) exhibited decreased cartilage matrix degradation by blocking the induction of 
MMP 1 and 13 and also inhibiting ADAMTs 4, 5 and 9 mRNA expression 275. The 
authors suggest that HDAC inhibitors could be used as chemo/therapeutic agents in OA 
due to their chondroprotective effects. Accepting these conclusions, the study did not 
directly address histone associated mechanisms involved in MMPs or ADAMTs 
suppression.  
Several recent studies by Roach and colleagues have established a link between 
altered CpG methylation and expression of degradative enzymes by articular 
chondrocytes in OA cartilage 260, 276-278. Roach and co-workers used 
immunohistochemistry to assess MMP-3, -9, and 13 and ADAMTS-4 expression by 
human OA chondrocytes. All four enzymes were present in late OA specimens and co-
localized to chondrocyte clusters. The methylation status of these CpG sparse promoters 
were assessed by methylation-sensitive restriction enzyme digestion followed by PCR 
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amplification. For all four enzymes, the overall demethylation percentage was increased 
and some sites were preferably demethylated in OA samples 276 . Similar results were 
obtained in subsequent experiments 277, 278. The authors suggest that demethylation of 
certain CpG dinucleotides is responsible for epigenetic de-silencing and expression of 
these enzymes in OA, although no experiments were carried out to test whether these 
specific sites were important for gene expression. Also there was no reference to whether 
the CpG sites in question lie in areas of transcription factor recognition. Therefore, more 
studies need to be done to prove that the observations above are responsible for 
epigenetic gene regulation of the degradative enzymes in OA or to find out that these are 
mere stochastic events resultant of activation of these enzymes by other means.  
IL-1β is a key cytokine involved in inflammatory responses and upregulation of 
degradative enzymes in osteoarthritis. Roach’s laboratory demonstrated that 5-aza-CdR 
upregulates IL-1β by human articular chondrocytes 260. Bisulfite conversion and 
sequencing showed that IL-1β was preferably demethylated at CpG site 299 bases 
upstream of the start site.  Interestingly, treatment with cytokines (TNF-α plus oncostatin 
M) was more effective than 5-aza-CdR in increasing IL-1β levels and also correlated with 
more -299 CpG demethylation in the IL-1β promoter region. Since TNF-α and oncostatin 
M do not have known demethylation properties, it is probable that other mechanisms are 
involved in active demethylation of the IL-1β promoter.  The authors suggest that NF-κB 
might play a role in demethylation of IL-1β promoters 279, since the -299 CpG site is 
within/adjacent a canonical NF-κB binding site.   
Work done by Simopoulou and others demonstrated that leptin might act as a link 
between obesity and osteoarthritis. Levels of leptin are increased in synovial fluid of 
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osteoarthritic joints. In addition, treatment of chondrocytes with leptin leads to 
upregulation of IL-1β, MMP-9 and 13 protein levels 280. In addition, the same group 
found that epigenetic mechanisms are involved in the regulation of leptin expression in 
osteoarthritic chondrocytes. DNA bisulfite sequencing was used to demonstrate that the 
leptin promoter is methylated in normal chondrocytes but demethylated in severe OA. 
Moreover, the use of small interference RNA against leptin down regulated MMP-13 
expression. Administration of 5-aza-CdR to normal chondrocytes demethylated the leptin 
promoter, upregulating leptin and its downstream target gene, MMP-13. Treatment with 
the HDAC inhibitor, TSA, also increased leptin expression by normal chondrocytes and 
correlated with H3K9 and K14 acetylation at the leptin promoter 259.    
 Not all changes in gene expression observed during osteoarthritis are associated 
with changes in promoter methylation profile. As examples, p21 281 and aggrecan 282 
down regulation in OA chondrocytes do not appear to be regulated by hypermethylation 
of the promoter sequences. Consequently, gene activation or repression is the result of 
interactions between transcription factors and epigenetic control.  
The majority of articles mentioned above do not show direct evidence that 5-aza 
exerts its effects on chondrocyte behavior by decreasing methylation at regulatory 
regions of target genes. Given the global epigenomic effects of 5-aza administration, 
mechanistically proving a functional consequence to specific gene expression is 
experimentally challenging, to say the least.  
Considering the increasing amount of information on epigenomic contributions to 
aging related disease, and the current amount of data associating epigenetic pathways in 
chondrocyte differentiation, phenotypic maintenance and the progression of OA, the 
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following studies were carried out to address the actions and mechanisms of 5-
azacytidine and genomic methylation in regulating of collagen type II expression by 
osteoarthritic chondrocytes (Chapter 3), in the phenotypic alterations that develop in OA 
chondrocytes (Chapter 4) and in the phenotypic differences between articular and 
endochondral chondrocyte populations (Chapter 5). 
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CHAPTER 3: PHENOTYPIC EFFECTS OF THE DNA METHYL-
TRANSFERASE INHIBITOR, 5-AZACYTIDINE, ON ARTICULAR 
CHONDROCYTES 
 
INTRODUCTION 
Articular cartilage is a specialized tissue that covers the articulating surfaces of 
bones. It is avascular and rich in extracellular matrix composed predominantly of water, 
collagen type II (Col II) and proteoglycans. Collagen fibrils anchored in the calcified 
cartilage plate provide the cartilage with tensile strength and resistance to surface shear, 
while the aggrecan: proteoglycan complexes bind water molecules and generate 
resistance to compressive loads 1, 2. Under normal circumstances, articular chondrocytes 
do not undergo hypertrophic maturation. Instead, articular chondrocytes persist 
throughout life in a nominally pre-hypertrophic state, characterized by the expression of 
Col II and aggrecan (Agg), with little or no expression of hypertrophic-specific genes 
such as collagen type X (Col X) and alkaline phosphatase (ALP) 3.  
The mechanism by which articular chondrocytes avoid hypertrophy is still not 
completely understood. There are several studies indicating that transforming growth 
factor-β (TGF-β) 4-6, bone morphogenetic proteins (BMP) 7-9, parathyroid hormone 
related peptide (PTHrP) 10-13 signaling pathways, in conjunction with transcriptional 
factors14-22 are crucial to maintenance of articular cartilage and articular chondrocytic 
phenotype. Interference with these signaling pathways leads to pathological changes that 
resemble osteoarthritis (OA) 4, 5, 7, 13.  
58 
 
OA is a non-inflammatory disease characterized by progressive articular cartilage 
degradation 23, calcification 24, and subchondral bone alterations 25. The disease is notable 
for the relative absence of neutrophil and macrophage infiltration, but high levels of 
inflammatory cytokines are produced by synoviocytes and chondrocytes 23, 26, 27, resulting 
in “inflammation-like” cell responses.  Although OA is predominantly characterized by 
loss of extracellular matrix homeostasis, the disease also causes distinct phenotypic 
alterations in the resident chondrocyte population. Articular chondrocytes undergo 
phenotypic changes resembling the transitions that occur during hypertrophic 
differentiation of endochondral lineage chondrocytes 28. Articular chondrocytes down-
regulate Col II and Agg expression 29, 30 and begin to express Col X 3, 31-34. This has been 
demonstrated by microarray comparisons 35 and differential Col X immunostaining in 
OA and normal cartilage 33, 36. Aberrant expression of other hypertrophic markers such as 
ALP and osteocalcin (OCN) has also been linked to OA 36, 37.  
In recent years, the role of epigenetic regulation in the control of cellular 
phenotype has been increasingly recognized. Epigenetics refers to “mechanisms that 
initiate and maintain patterns of gene expression and gene function in a heritable manner 
without changing the sequence of the genome” 38. Epigenetics impact gene regulation 
though DNA methylation, histone protein modifications and consequent chromatin 
organization. Overall, DNA methylation of CpG islands is associated with histone 
hypoacetylation that collectively repress transcription. DNA methyltransferases 
methylate cytidines at CpG dinucleotide sites. This modification can interfere with the 
recognition and attachment of DNA binding proteins to genomic cis elements. 
Additionally, methyl-CpG binding proteins are recruited to methylated CpGs (mCpG) 
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and, in turn, recruit histone deacetylases (HDACs), histone methyltransferases (HMTs) 
and chromatin-remodeling factors to methylated regions. These modifications condense 
chromatin structure, sequestering potential binding sites from transcriptional activators 
and restricting occupancy. As a consequence, transcription is repressed 39. However, 
promoter occupancy does not depend solely in its epigenetic state. Transcription 
activation and repression are also regulated by competitive binding of promoter, enhancer 
and silencer elements 40-45. Therefore, activation or repression of a gene is a collective 
consequence of the interplay of transcription factors and epigenetic constraints.   
Epigenetic processes are involved in regulation of germline-specific genes, tissue-
specific genes, imprinting, and aging 38. A growing body of evidence indicates that 
epigenetics is also critical in a range of disease processes. Cancer cells are often globally 
hypomethylated, although specific tumor suppressor genes are hypermethylated and 
transcriptionally suppressed 46. Several studies have demonstrated the importance of 
epigenetics in stem cell differentiation and lineage commitment 47-50. In addition, 
genome-wide screens have documented distinct methylation profiles in specific tissues 48, 
51-54, implicating CpG methylation in lineage commitment and phenotypic maintenance.  
Several recent studies have demonstrated the importance of epigenetic gene 
regulation in chondrocyte development and homeostasis. Vega et al (2004) 55 
demonstrated that HDAC4 functions as a negative regulator of chondrocyte hypertrophic 
differentiation by suppressing the activities of Runx2, a transcription factor required for 
hypertrophy. HDAC activity is also necessary to support collagen type II expression in 
articular chondrocytes, and permit re-differentiation of (monolayer) de-differentiated 
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chondrocytes 56. In this context, HDAC activity was linked to suppression of Wnt-5A 
expression, a protein known to suppress the chondrocytic phenotype.  
DNA methylation has been indirectly implicated in chondrocyte differentiation. 
The DNA methyltransferase inhibitor, 5-azacytidine (5-aza), induced expression of 
hypertrophic markers in chick articular chondrocytes 57, suggesting that epigenetic 
pathways regulate the lineage commitment of chondrocyte populations. Cheung et al 
(2001)58 observed similar results in bovine fetal epiphyseal chondrocytes treated with 5-
aza. 
A series of studies from the Asahara lab have established that the histone 
acetyltransferase, CBP/p300, associates with Sox-9 to regulate transcription of the Col II 
gene in chondrocytes 59. Moreover, trichostatin A, a histone deacetylase inhibitor, 
stimulates expression of Col II and Agg, and increases nucleosomal acetylation around 
the Sox-9 binding site 60. Taken together, these results support a model whereby the gene-
specific factor Sox-9 interacts with chromatin-remodeling factors to activate Col II 
transcription.  
Epigenetic pathways have also been implicated in the pathogenesis of OA. HDAC 
inhibitors (trichostatin A or sodium butyrate) decreased cartilage matrix degradation by 
blocking the induction of matrix metalloproteases (MMP) 1 and 13 and also inhibiting 
ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) 4, 5 and 9 
mRNA expression by bovine nasal cartilage explants co-treated with cytokines 61. In 
addition, Roach and others, have linked osteoarthritic changes in articular chondrocyte to 
demethylation of specific CpG dinucleotides in MMP-3,9,13 and ADAMTS-4 62-64 
promoters that result in epigenetic de-silencing of these genes in OA. In addition, 
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epigenetic mechanisms are also involved in regulating leptin expression in osteoarthritic 
chondrocytes 65. The leptin promoter is methylated in normal chondrocytes but 
demethylated in severe OA cells. Leptin expression activates MMP-13 in chondrocytes 
65.  Furthermore, treatment of normal chondrocytes with 5-aza-2-deoxycytidine (5-aza-
CdR) demethylates the leptin promoter, and upregulates expression of leptin and its 
downstream target MMP-13 65.  Ho, et al (2006)66 showed that human articular 
chondrocytes cultured in alginate beads and treated with 5-aza undergo phenotypic 
changes that resemble hypertrophy; somewhat analogous to the phenotypic changes that 
occur in OA.  
A number of age-related diseases, including atherosclerosis, neurologic disorders, 
cancer, and autoimmune diseases, have been linked to altered cell function due to 
epigenetic alterations 67. The clinical incidence of osteoarthritis is increased in older 
individuals and, as discussed above, upregulation of several catabolic enzyme genes 
during OA appears to be linked to demethylation of their promoters. In addition to the up-
regulation of inflammatory cytokines and degradative enzymes in OA, the expression of 
critical ECM genes, particularly the major cartilage-specific collagen type II, is reduced 
in OA chondrocytes. In this study we assessed the effect of 5-aza administration to OA 
chondrocytes on collagen type II expression, determined the CpG methylation status of 
the collagen type II promoter and Sox 9 enhancer sequences in chondrocytes and non-
chondrocytic cell types and investigated whether expression of collagen type II in OA 
chondrocytes is linked to the methylation status of its promoter/enhancer regions. 
 
 
62 
 
METHODS 
 
Sample collection 
Human articular cartilage and bone were obtained from donors following total 
knee replacement procedures at Carle Clinic, Urbana, IL. This project was approved by 
both the University of Illinois Ethics Committee and the Carle Clinics Ethics Committee. 
Informed consent was obtained from the patients before surgery.   
The articular cartilage specimens presented with variable degrees of degeneration, 
both between and within specimens. Therefore, articular cartilage was collected 
according to its macroscopic characteristics, i.e. samples that were not fibrillated were 
considered “normal”; whereas cartilage samples with surface irregularities were 
considered to be overtly osteoarthritic. Severely degenerative tissues and osteophytic 
cartilage were excluded from the collections. Cancellous bone was harvested from the 
central region of the proximal tibia fragment. One to two grams of cartilage and bone 
were snap frozen in liquid nitrogen and stored at -80°C for until needed for DNA 
isolation. 
 
Chondrocyte isolation 
Articular cartilage specimens were diced, washed in phosphate buffered saline 
(PBS) (HyClone, Logan, UT) and transferred to 500-mL Ehrlenmeyer flasks. The 
cartilage explants were pre-digested in 0.3% pronase (Roche Diagnostics Corporation, 
Indianapolis, IN)  reconstituted in Opti-MEM (Gibco, BRL-Life Technologies, Grand 
Island, NY) supplemented with penicillin G sodium (200 units/mL) streptomycin (200 
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µg/mL) (Gibco), 2.5 µg/mL of amphotericin B (Cellgro, Mediatech, Inc, Herndon, VA) 
and 2% of fetal bovine serum (Gemini Bio products, West Sacramento, CA), at 10 mL/g 
of cartilage. The flasks were placed in a C24 shaking incubator (New Brunswick 
Scientific, Edison, NJ) at 180 rpm at 37°C for an hour. After one hour, the pre-digestion 
solution was aspirated, the explants were rinsed with PBS and were resuspended in 
0.15% collagenase A (10 mL per gram of tissue; Roche) reconstituted in Opti-MEM 
supplemented with penicillin G sodium (200 units/mL) streptomycin (200 µg/mL), 
2.5µg/mL of amphotericin B and 2% of fetal bovine serum was added to the flask for the 
overnight digestion in the C24 shaking incubator at 180 rpm at 37°C.  
After the overnight digestion, the cell suspension was filtered through a 40-
micron filter (Nalgene Company, Fisher Scientific, Pittsburgh, PA) into 50-mL Falcon 
tubes (Fisher Scientific). The flask and filter were rinsed with PBS to recover any 
residual cells.  After filtration, the cells were pelleted by centrifugation (Centrifuge 5810 
R, Eppendorf, Westbury, NY) for 10 minutes at 290 rcf. The supernatant was aspirated 
and the cell pellet was re-suspended in PBS and pelleted following the same protocol to 
assure removal of residual collagenase. Finally, the cells were resuspended in 10-20 mL 
of Opti-MEM for cell counting and viability assessment.  
 
Cell count and viability  
 The cell numbers were calculated by counting chondrocytes in an aliquot of the 
resulting suspension using a hematocytometer (Fisher Scientific) and inverted light 
microscope (Fryer Co. Inc., Huntley, IL).  Two vials containing a 1:10 dilution of the cell 
suspension and 10% Trypan blue dye (Gibco) were prepared.  The samples were mixed 
64 
 
and 10 µL were added to each side of the hematocytometer. Dead and live cells were 
counted in a total of 9 (1 mm2) squares in each side. The total number of cells in the cell 
suspension was obtained by the following formula:  
# of cells = # of cells counted/18 (# of 1 mm2 squares counted) x 10 (cell dilution) x 10 or 
20 (total volume of the cell suspension) x 104 
  
Chondrocyte culture conditions 
Articular chondrocytes (3 to 4 million cells per well) were cultured as non-
adherent aggregates using a defined serum-free culture medium (Opti-MEM, Gibco) in 
hydrogel-coated, ultra low attachment culture plates (six-well plates (10 cm2 wells)) 
(Corning Costar, Pittsburgh, PA) or as monolayers (50,000 cells per cm2  in 100 mm2 
culture plates (Corning Costar), in 10mL of medium).  Opti-MEM is a proprietary 
medium, based on alpha MEM and supplemented with insulin, transferrin and selenous 
acid (ITS). It was originally developed for low-serum growth of hybridoma cultures, but 
also supports chondrocyte cultures very well 68, 69. The media was supplemented with 
ascorbic acid (Sigma-Aldrich, St. Louis, MO) (50 µg/mL) penicillin G sodium (100 
units/mL) and streptomycin (100 µg/mL).  The culture medium was changed every two 
to four days depending on cellular metabolism.  Cultures were maintained at 37°C, in 
95% air/ 5% CO2 in a humidified incubator (Fisher Scientific). After 24 hours of seeding, 
the chondrocytes were treated or not with 10 µM of 5-azacytidine (Sigma-Aldrich) for 4 
days (non-adherent aggregates) or 15 days (monolayers). If the media needed to be 
changed before collection, a freshly prepared 5-aza solution was added to the media. This 
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treatment interval provides ample opportunity for at least one round of cell division, and 
consequent 5-aza incorporation.  
 The chondrocyte aggregates were collected by transferring the aggregates and 
media from each well into a 15-mL Falcon tube.  The monolayer cultures were washed 
with cold PBS then immediately lysed in TRIzol (see below). The lysates were aspirated 
from the plates and transferred to 15-mL Falcon tubes. For DNA collection, monolayers 
were washed with PBS, scraped directly off the plates and transferred to 15-mL Falcon 
tubes. The 15-mL tubes were centrifuged in a refrigerated centrifuge (Eppendorf) at 290 
rcf for 10 minutes. After pelleting, the media were aspirated from the samples and the 
pelleted cells were snap frozen in liquid nitrogen and stored at -80°C until processed. 
 
Cell line culture conditions 
TC-28a4, HTB94, U2OS, SAOS-2 and HeLa cell lines were seeded at 20,000 
cells/cm2 in 100 mm2 culture dishes (Corning Costar) and cultured as monolayers in 10 
mL of DMEM (Dulbecco's Modification of Eagle Medium, Mediatech Inc., Manassas, 
VA) supplemented with 10% fetal bovine serum (Gemini Bio products, West 
Sacramento, CA) penicillin G sodium (100 units/mL) and streptomycin (100 µg/mL).  
The culture medium was changed every two to four days depending on cellular 
metabolism.  Cultures were maintained at 37°C, in 95% air/ 5% CO2 in a humidified 
incubator (Fisher Scientific). After 24 hours of seeding, the HeLa cells were treated or 
not with 10 µM of 5-aza (Sigma-Aldrich) for 4 days. If the media needed to be changed 
before collection, a freshly prepared 5-aza solution was added to the samples treated with 
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5-aza.This treatment interval provides ample opportunity for at least one round of cell 
division, and consequent 5-aza incorporation.  
 Samples for RNA and DNA isolation were handled as for chondrocyte monolayer 
cultures, above.  
 
RNA isolation 
 Total RNA was isolated from the chondrocyte aggregates using phenol-based 
dissociation agent, TRIzol® (Invitrogen Corporation, Carlsbad, CA).  One milliliter of 
TRIzol® was added to the frozen aggregate pellet and the sample was immediately 
homogenized using an Ultra-Turrax T25 homogeneizer (Janke & Kunkel, IKA-
Labortechnik, Staufen, Germany) for 30 seconds.  The samples were then centrifuged in a 
refrigerated centrifuge 5810 R (Eppendorf) at 453 rcf for 10 minutes to precipitate the 
insoluble debris.  The TRIzol® supernatants were transferred to 1.5-mL microcentrifuge 
tubes (Eppendorf) and 200 µL of chloroform per milliliter of TRIzol® was added to 
separate the aqueous and organic phases of the lysate.  After vortexing, the tubes were 
centrifuged in a refrigerated centrifuge (Centrifuge 5415 R, Eppendorf) at 16,100 rcf for 
20 minutes at 4°C. The upper aqueous phase (approximately 400 µL) was removed and 
placed in a new 1.5-mL microcentrifuge tube.  During this step, great care was taken to 
leave the insoluble material at the interface intact. This interface material is comprised of 
insoluble proteins, lipids, DNA and, with chondrocyte cultures, large amounts of 
proteoglycans. To maximize RNA yields, the remaining aqueous volume and a small 
amount of the interface (400 µL) was then transferred to a 0.5-mL microcentrifuge tube 
67 
 
(Fisher). These smaller tubes were then centrifuged at 16,100 rcf and an additional 100-
200 µL of aqueous phase was transferred to the 1.5-mL microcentrifuge tubes. 
The RNA was precipitated from the aqueous solution by addition of 250 µL of 
isopropanol and 250 µL of 1.2 M sodium chloride/0.8M sodium citrate. This high-salt 
precipitation protocol minimizes co-precipitation of proteoglycans. The microcentrifuge 
tubes were stored overnight at -20°C to facilitate RNA precipitation.  The samples were 
then centrifuged at 16,100 for 30 minutes at 4°C to pellet the RNA.  The pellet was 
washed with 500 µL of 70% ethanol to reduce the salt content of the pellet, and allowed 
to air dry for 10 minutes.  The pellet was dissolved in diethyl pyrocarbonate (DEPC)-
treated water.  A 1:40 aliquot of each sample was used to quantify the nucleic acid 
concentration spectrophotometrically (SmartSpecTM 3000, Bio-Rad, Hercules, CA), using 
optic density (OD) values at 260 and 320 nM. The concentration of total RNA was 
calculated as follow:  
RNA in µg/µL= OD at 260 nM – OD at 320 nM x 40 (dilution factor) x 40(coefficient) 
                    1000 
 
Northern blot analyses 
Four micrograms of total RNA were brought up to 90 µL using DEPC-treated 
water then 10 µL of 3 M Na acetate pH 5.2 and 300 µL of 100% ethanol were added. The 
samples were stored overnight at -20°C to allow the RNA to precipitate. The samples 
were then centrifuged at 16,100 for 30 minutes at 4°C, the pellet was washed with 500 
µL of 70% ethanol, air-dried for 10 minutes and reconstituted in 20 µL of sample buffer. 
The sample buffer constituted 600 µL of formamide, 240 µL of DEPC-treated water, 160 
µL of formaldehyde, 100 µL of 10x MOPS, 100 µL of blue dye (50% formamide, 50% of 
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80% glycerol and bromophenol blue) and 10 µL of ethidium bromide. The samples were 
placed on ice for 5 minutes and then transferred to a 65°C water bath for 15 minutes to 
completely solubilize the RNA.  The samples were loaded in a 1% agarose/formaldehyde 
gel to allow transcript size separation by electrophoresis in MOPS buffer. To maintain a 
constant ionic gradient during the 3-hour electrophoresis process, the gel was elevated 
above the surface of the electrophoresis platform using glass rods, and the buffer was re-
circulated between the electrodes with a peristaltic pump (Mini-pump variable flow, 
Fisher Scientific). After RNA electrophoresis, the integrity of RNA samples was verified 
by visualization of ethidium bromide-stained ribosomal bands under ultra-violet light 
(High Performance Ultraviolet Transilluminator, UVP, LLC, Upland, CA). The 
electrophoresed RNA was transferred from the gel onto nylon membranes (GE 
Infrastructure, Minnetonka, MN) by overnight capillary transfer using a high-salt (10X 
SSC) transfer solution. After transfer, the membranes were washed in 5X SSPE at 60°C 
to remove adherent agarose and salts, then the transferred RNAs were immobilized to the 
nylon substrate by UV irradiation crosslinking (Spectrolinker XL-1000 UV crosslinker, 
Spectronic Corporation, Westbury, NY). 
For Northern blot hybridization, membranes were re-hydrated, rinsed in 5xSSPE 
and then pre-hybridized at 65°C in a rotating hybridization oven for 1-2 hours in pre-
hybridization solution (5X SSPE, 5 X Denhardt’s solution (Eppendorf), 0.25% SDS 
(Fisher Scientific), 10% dextran sulfate (Fisher Scientific)) and 150 µg/mL denatured 
salmon sperm DNA (Invitrogen). Isotopic probes were prepared by random-primed 
labeling, using a commercial labeling kit (Prime-it® II, Stratagene, Cedar Creek, TX) and 
32P-dCTP (Amersham, Piscataway, NJ).  The probes were purified using G-50 Sephadex 
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spin columns (Boehringer-Mannheim, Indianapolis, IN), denatured and then added to 
hybridization tubes containing the pre-hybridized membranes.  
After overnight hybridization, the membranes were rinsed in 2X SSPE, 0.5% 
SDS. Sequential washes were done until the washing solution reached 0.5xSSPE with 
0.125% SDS and the membrane background activity was minimal, as assessed by a 
handheld Geiger counter GSM-110 (Wm. B. Johnson & Associates, Inc., Fairlea, WV). 
The membranes were wrapped in Saran plastic and exposed overnight to a phosphor 
screen (Packard Instrument Comp, Inc., Meridan, CT) for quantitative analyses of signal 
intensity with Cyclone Storage Phosphoscreen (Packard). Finally, the membranes were 
exposed to autoradiograph film (Kodak Bio-Max MS Film, Carestream Health, Inc., 
Rochester, NY) for “hardcopy” recording of membrane activity. Radiograph cassettes 
were stored overnight at –80°C.  Details of the primers used to generate cDNAs for 
Northern blot probes are provided in Table 1. 
 
Reverse transcription  
First strand cDNA was synthesized by reverse transcription using First Strand 
cDNA Superscript II (Invitrogen) and Oligo dT as per manufacturer’s instructions. 
Briefly, one microgram of total RNA was brought up to 10 µL and then combined with 1 
µL of oligo (dT) (0.5µg/µL) and 1 µL of 10 mM dNTPs. The sample was incubated in a 
65°C water bath for 5 minutes and then placed on ice for 1 minute to denature the RNA 
and allow binding of the oligonucleotides.  The following reagents were added: 2 µL 10x 
First Strand Buffer, 2 µL 0.1M DTT, 2 µL 50 mM MgCl2 and 1 µL RNase out. After a 
gentle mix and brief centrifugation, the sample was incubated at 42°C water bath for 2 
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minutes, 1 µL (50 units) of SuperScript II Reverse Transcriptase was added. The sample 
was then incubated at 42°C for 50 minutes. The reaction was stopped by placing the 
sample in a 70°C water bath for 15 minutes.  The RT reactions were diluted (1:10 ratio) 
with water and stored at -20°C until further use. 
 
Quantitative polymerase chain reaction (qPCR) 
 Quantitative PCR (qPCR) was used to compare gene expression profiles of 
different cartilage samples. The PCR reactions were carried out in a final volume of 25 
µL.  The 2x SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) was used for 
these reactions. This reagent contains  100 nM KCl, 40 mM Tris-HCl, 0.4 mM of each 
dNTP, 50 units/mL of Taq polymerase, 6 mM MgCl2, and 20 nM SYBR Green I.  The 
SYBR Green Supermix (12.5 µL) was added to 1 µL of the sense (10 pMol) and 1 µL of 
the antisense primers.  Autoclaved distilled water (5.5 µL) and 5 µL of cDNA template 
were also added. Initial denaturation step was carried out at 95°C for 3 minutes, then 45 
cycles of denaturation at 95°C for 10s, annealing temperature of 62°C for 30s and 
polymerase extension at 72°C for 20s followed. The samples were denatured at 95°C for 
1 min before starting the melting curve protocol that consisted of decreasing the 
temperature at 55°C for 1 minute followed by increments of 0.5°C every 10 s till 95°C 
was reached. The primers used for qPCR analyses are listed in Table 2. The primer 
combinations used in these experiments were designed for annealing at 60-62°C, 
however optimal annealing temperatures were determined by temperature gradient 
analyses spanning 54-64°C. The specificity of the PCR products was monitored by 
melting curve analyses, PCR fragment cloning and sequencing. Quantitative results were 
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accessed using the cycle threshold determined to represent the onset of the linear phase of 
amplification, as calculated by the thermal iCycler software (Bio-Rad). Sterile water was 
used as a ‘no template’ negative control for each of the PCR reactions as to monitor the 
possibility of contamination. The qPCR data were normalized to expression of the 
reference gene, elongation factor-1 alpha (EF1α). 
  
DNA extraction 
 Approximately 200 mg of powdered cartilage or bone was digested overnight in 
2 mL of proteinase K digestion buffer (100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 25 mM 
EDTA (pH 8.0), 0.5% SDS, 0.1 mg/mL of proteinase K) at 50°C. The DNA was 
extracted in 1 mL of phenol and 1 mL of chloroform: isoamyl alcohol (24:1). After 
vortexing, the sample was centrifuged at 8,100 rcf for 10 minutes in a bench top 
centrifuge (Denville 260 D, Denville Scientific Inc., Metuchen, NJ) to separate the 
organic and aqueous phases. The aqueous supernatant was transferred to a new 
microcentrifuge tube and 500 µL of 7.5 M ammonium acetate and 2 mL of 100% ethanol 
were added. The sample was mixed by inversion of the tube and allowed to precipitate at 
room temperature for 5 minutes before being centrifuged at 8,100 rcf for 2 minutes. The 
supernatant was discarded and the pellet was washed with 70% ethanol, air dried and 
reconstituted in 270 µL of TE buffer. The sample was re-precipitated overnight at -20°C 
using 30 µL of 3 M sodium acetate and 900 µL of 100% ethanol. The sample was 
pelleted at 8,100 rcf for 10 minutes, washed in 70% ethanol, air dried, resuspended in 200 
µL of TE buffer and quantified by UV spectrophotometry. The sample was stored at -
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20°C until needed. The same procedure was used to isolate DNA from chondrocytes (1.5-
8 million cells), however the reaction had the volume reduced by 50%. 
 
Methylation-sensitive restriction enzyme digestion  
 Methylation-sensitive restriction enzyme digestion was used to determine whether 
collagen type II expression by human osteoarthritic chondrocytes and the effects of 5-aza 
treatment correlate with methylation of cytidines at CpG dinucleotides. Thirteen primer 
pairs spanning approximately 1,200 bp upstream and 3,500 bp downstream of the Col II 
transcription start site were designed to comprehensively assess the promoter and first 
intronic Sox 9 enhancer sequences. For these analyses, the Col II methylation status of 
five human cell lines (chondrocytic TC-28a4, HTB-94, osteoblastic U2OS, SAOS-2 and 
non-skeletal HeLa cell lines), cartilage and bone samples from four individuals and three 
experiments comparing the methylation status of control and 5-aza-treated cells was 
assessed.  
Five hundred nanograms of genomic DNA extracted from articular cartilage, bone 
or cells, were digested or not (control) with the methylation-sensitive restriction enzymes 
HpaII (New England Biolabs, Ipswich, MA)  or HhaI (New England Biolabs) (Figure 1). 
The methylation-resistant restriction enzyme MspI (HpaII isosquizomer) (New England 
Biolabs) was used to control for complete digestion of the DNA.  DNA digestion was 
carried out in a 40 µL reaction volume overnight at 37°C. EcoRV (Invitrogen) was also 
added to the digestion solutions to reduce the fragment size of the genomic templates. 
Twenty units of each enzyme were added to the digestion reactions to ensure complete 
digestion of the genomic DNA (One unit is defined as the amount of enzyme required to 
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digest 1 µg of λ DNA in 1 hour at 37°C in a total reaction volume of 50 µL). The 
restriction digestion was stopped by heating the samples at 65°C for 25 minutes. The 
samples were diluted with 40 µL of water. Primers targeting the Cyclin D1 promoter 
were used as controls for demethylation since previous experiments demonstrated that the 
Cyclin D1 promoter is unmethylated in chondrocytes (unpublished data). Primers 
targeting the imprinted gene H19 were used as positive controls for methylation. Primers 
and annealing temperatures are listed in Table 3. To screen for potential DNA 
contamination, sterile water was used as a ‘no DNA template’ control. 
. 
Polymerase chain reaction amplification 
Two microliters of the diluted samples (12.5 ng DNA) were used as templates for 
PCR reactions. The PCR reaction (25 µL) contained 2.5 µL of 10x PCR buffer 
(Invitrogen), 1 µL of 50 mM MgCl2, 0.5 µL of 10 mM dNTPs (Invitrogen), 10 pMol of 
the sense primer, 10 pMol of the antisense primer and 0.3 µL of Taq DNA polymerase 
(Invitrogen), in addition to the DNA template. The protocol for the PCR reaction was as 
follows: 95°C denaturation for 5 minutes, 30 cycles of denaturation at 95°C for 30 s, 
annealing at 62-66°C for 30 s, extension at 72°C for 20 s, followed by 1 cycle at 72°C for 
10 min and 4°C indefinitely. The PCR products were separated by electrophoresis using a 
2 % agarose TAE gel.        
                     
Band interpretation 
The gels were stained with ethidium bromide and photographed using a Kodak 
EDAS 290 system (Carestream Health) for band intensity comparison between control, 
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samples and those digested with HpaII, HhaI or MspI. Absence of bands in the MspI-
digested sample indicated complete DNA digestion. Absence of bands in the HpaII- and 
HhaI-digested samples indicated complete demethylation of at least one CpG in the DNA 
template. The presence of faint bands in samples digested by HpaII or HhaI indicated 
methylation of the DNA in part of the cell population and a strong band indicated 
methylation of the tested CpG dinucleotides in most, if not all, cells of the population.  
 
Bisulfite conversion and sequencing 
 The methylation status of the promoter/enhancer region of the collagen type II 
gene was analyzed by bisulfite conversion and sequencing using articular cartilage 
collected from six individuals that underwent total knee replacement procedures. The 
articular cartilage was diced, snap frozen and stored at -80°C. After being pulverized 
under liquid nitrogen, genomic DNA was isolated by proteinase K digestion followed by 
phenol/chloroform extraction and ethanol precipitation as described above. One 
microgram of genomic DNA was bisulfite-converted using the EZ DNA Methylation™ 
kit (Zymo Research, Orange, CA) following the manufacturer’s instructions. Bisulfite 
conversion transforms unmethylated cytidines to uridines that are further substituted by 
thymidines during subsequent PCR amplification. Two primer pairs were designed to 
span 700 bp of the promoter region (237 bp upstream of the transcription start site and 
463 bp downstream of the transcription start site) and one primer pair was designed to 
span 298 bp of the collagen type II enhancer that contains the Sox-9 binding site. The 
following guidelines were used to design the primers: 
1) All non-CpG cytidines were considered to be converted to thymidines 
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2) Between three and four non-CpG cytidines (thymidines after conversion) were 
included in each primer, to select for fully converted templates 
3) Primers did not span CpG dinucleotides 
4) Each primer pair span between 200 and 500bp. As a consequence, several 
primer pairs were used to comprehensively interrogate the methylation status of the Col 
II promoter and enhancer sequences within the gene’s CpG islands and known to be 
critical for transcriptional regulation (Figure 2).  
PCR amplifications were performed as described for PCR following restriction 
enzyme digestion. Two microliters of bisulfite converted DNA were used as template. 
The protocol for the PCR reaction was as follows: 95°C denaturation for 5 minutes, 45 
cycles of denaturation at 95°C for 30 s, annealing at 55-60°C for 30 s, extension at 72°C 
for 20 s, followed by 1 cycle at 72°C for 10 min and 4°C indefinitely. The PCR products 
were separated by electrophoresis using a 2 % agarose TAE gel. Primer sequences and 
annealing temperatures are listed in Table 4. PCR products were cloned using TOPO 
PCR II TA cloning kit (Invitrogen), as per manufacturer’s instructions. Six clones from 
each target site were sent to be sequenced by the University of Illinois Core Sequencing 
Facility.  
 
p21 and p53 transfection studies 
Two to four million cells were cultured as non-adherent aggregates using a 
defined serum-free culture medium (Opti-MEM, Gibco). Twenty four-well (2 cm2 wells)  
hydrogel-coated, ultra low attachment culture plates (Corning Costar, Pittsburgh, PA) 
were seeded with 1 million cell per well for the experiment that had 2 million cells per 
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treatment, whereas six-well (10 cm2 wells) were used for the experiment that had 4 
million cells per treatment. Cell culture conditions were as described above. After 24 
hours of seeding, the chondrocytes were treated or not with 10 µM of 5-aza (Sigma-
Aldrich) for 4 days, or transfected with adenoviral vector expressing p21, p53 or LacZ 
(control) cDNA at three different concentrations (2, 10 or 25 infectious particles per cell). 
Infection was performed in 1 mL of media (10 cm2 wells) over four hours with occasional 
shaking. After four hours, 5 mL of fresh media was added and the samples were collected 
on day 4 as previously described. For the experiment that used 2 cm2 wells, transfection 
was performed in 200 µL of media and 1.3 mL was added after the 4 hour incubation 
with occasional shaking. After pelleting, the media were aspirated from the samples and 
the pelleted aggregates were snap frozen in liquid nitrogen and stored at -80°C until 
processed. The adenoviral vectors were purchased from The University of Michigan’s 
Vector Core laboratory. Collagen type II and EF1-α gene expression was assessed by real 
time PCR as described above.  
 
Statistical analysis 
 Statistical analyses were carried out using GraphPad Prism version 3.0 software.  
Comparisons between groups were made by two-way ANOVA.  Dunnet’s post-hoc test 
was applied when appropriate to assess the significance of differences between controls 
and experimental groups within each experiment. For all analyses, a p value of < 0.05 
was considered to be significant.   
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RESULTS 
Effects of 5-azacytidine on chondrocyte matrix gene expression  
In non-adherent aggregate culture conditions, collagen type II expression by 
articular chondrocytes treated with 5-aza for 4 days was significantly greater (p= 0.0049 ) 
than control expression, as demonstrated by quantitative PCR and Northern Blot analyses 
(Figure 3). Further, 5-aza administration maintained collagen type II expression in 
monolayer culture; conditions that normally lead to phenotypic de-differentiation and loss 
of collagen type II expression 9, 68 (Figure 4).   
To investigate whether the effects of 5-aza were specific to collagen type II or 
affected the expression of other cartilage matrix genes, we performed quantitative PCR 
analyses of several other extracellular matrix genes. Collagen type I is not normally 
expressed by articular chondrocytes, and was therefore it was used as controls. Collagen 
type X is usually expressed by hypertrophic chondrocytes but not by articular 
chondrocytes; therefore, Col X expression was assessed to investigate whether 5-aza 
alters the chondrocytic phenotype as previously described 57, 58, 66.   
5-aza significantly up-regulated the expression of aggrecan, collagen types IX and 
XI, and link protein (Figure 5). Other extracellular matrix genes, such as collagen type VI 
and cartilage oligomeric matrix protein (COMP), were not affected, indicating that the 
upregulation of chondro-specific genes was not the consequence of a general effect on 
gene expression by 5-aza. Of note, collagen type I and type X were not affected, 
indicating that articular chondrocytes treated with 5-aza did not undergo de-
differentiation or hypertrophy.     
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CpG methylation status of the collagen type II promoter and enhancer in human 
cell lines  
Given that the collagen type II gene promoter and chondrocyte-specific Sox-9-
responsive enhancer are enclosed in CpG islands, and DNA methylation of CpG islands 
can impact gene expression, we investigated whether expression of collagen type II is 
associated with changes in the methylation status of these sequences. 5-aza is known to 
be incorporated into DNA as a cytidine analog during DNA replication. It covalently 
binds Dnmt1 70, 71 sequestering the enzyme and leading to a global reduction in genomic 
methylation 72, 73.  
In the first series of experiments, the methylation profiles of the collagen type II 
promoter and Sox 9 enhancer were assessed in chondrogenic (TC28a4 and HTB94), 
osteogenic (SAOS-2 and U2OS) and a generic (HeLa) cell lines. The methylation status 
of the 4,686 bases encompassing the promoter and enhancer CpG islands was analyzed 
by methylation-sensitive restriction digestion followed by PCR amplification (Figure 6). 
The methylation status of collagen type II varied among different cell lines and was 
specific to each cell line rather than showing phenotypic consistency or reflecting the 
expression status of collagen type II.  
 
CpG methylation status of the collagen type II promoter and enhancer in primary 
human chondrocytes and osteoblasts  
It has been recognized that the epigenetic profiles of cell lines do not necessarily 
reflect the epigenetic profiles of primary cell types from which they are derived 74. 
Therefore, we compared the methylation profiles of the Col II promoter and enhancer in 
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four paired articular cartilage and bone samples, collected from the same donors. The 
effect of monolayer de-differentiation on the methylation status of the Col II 
promoter/enhancer was also assessed by comparing passage 1 and passage 12 samples.  
The Col II promoter/enhancer CpG islands contained very little methylation in 
either cell type and methylation patterns were not consistent within the cell types. 
Further, multi-passage monolayer de-differentiation did not alter the Col II methylation 
profile (Figure 7). In summary, the Col II promoter/enhancer methylation status did not 
reflect collagen type II expression in these ‘primary cell’ experiments. 
 
The effect of 5-aza on collagen type II promoter and enhancer CpG methylation 
To determine whether 5-aza administration was affecting the CpG methylation 
status of the Col II promoter/enhancer CpG islands, methylation-sensitive restriction 
digestion, followed by PCR amplification, was applied to DNA samples from three 
‘control’ and ‘5-aza treated’ samples where transcriptional up-regulation of collagen type 
II was previously confirmed (as in Figure 3). HeLa cells were also included as a generic 
control for these experiments. The result of these experiments demonstrated that Col II 
up-regulation after 5-aza treatment was not associated with altered methylation of the 
collagen type II promoter/enhancer sequences (Figure 8). In fact, no CpG demethylation 
was apparent in any sample.  
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Comprehensive analysis of collagen type II promoter and enhancer CpG 
methylation by bisulfite conversion and sequencing  
Restriction enzyme-based analyses of CpG methylation status are constrained to 
CpG sites within appropriate cleavage sites. To overcome these limitations, the 
methylation status of the collagen type II promoter and enhancer CpG islands in articular 
cartilage samples from six human donors were analyzed by bisulfite conversion and 
sequencing since this technique evaluates every CpG within the targeted sequence. Sixty-
eight CpG sites in the promoter island and 17 CpG sites in the first intronic Sox-9-
responsive enhancer were assessed by bisulfite conversion. 
The bisulfite conversion results supported the previous findings that the collagen 
type II promoter and enhancer contain very few methylated CpGs and these methylation 
sites varied between individuals. The bisulfite conversion results from the enhancer 
analyses are presented in Figure 9. The promoter CpG island analyses were similar in the 
sporadic and infrequent distribution of methylated CpG sites. 
 
Potential transcription factor targets of 5-aza  
Several transcription factors are known to regulate chondro-specific extracellular 
matrix gene expression and, more generally, the chondrocytic phenotype. As examples, 
during chondrogenesis, Sox-9, L-Sox-5 and Sox-6 control the expression of several 
chondrocyte-specific genes such as Col II, aggrecan, Col XI and link protein 14-22 In 
contrast, Snail and Slug repress expression of both Col II and aggrecan 75. Therefore a 
gene candidate approach was used to investigate the expression of transcription factors 
known to influence expression of Col II in articular chondrocytes following 5-aza 
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treatment. The expression of transcription activator Sox-9 and p63, which drive 
expression of chondrocytic genes, were not up-regulated by 5-aza treatment. Further, the 
expression of several transcriptional repressors known to inhibit expression of the 
chondrocytic phenotype, such as twisted gastrulation, slug, and Ids 1-4 were not down-
regulated by 5-aza (Figure 10). It does not appear that 5-aza alters Col II expression by 
influencing expression of transcription factors that regulate transcription of the collagen 
type II gene. 
 
Potential growth factor targets of 5-aza  
Several growth and differentiation factors are known to support the chondrocytic 
phenotype and increase the expression of cartilage matrix genes; in particular, members 
of the TGF-β and BMP ligand superfamily.  Increased expression of one or more of these 
factors could account for the increased expression of Col II and other matrix genes, 
following 5-aza exposure (Figure 5).  
Quantitative PCR analyses of growth factor expression after 5-aza administration 
showed that TGF-β3 and its downstream effector, connective tissue growth factor 
(CTGF), were significantly upregulated by 5-aza (Figure 11). However, we were not able 
to analyze the TGF-β3 promoter region to verify whether this upregulation correlated 
with altered methylation of the promoter region.  
 
Potential collagen type II up-regulation by p53/p21 activation  
5-aza also induces cellular responses following genomic incorporation, through 
activation of the DNA damage response. This response leads to p53 activation, 
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p21Waf1/Cip1 up-regulation and cell cycle arrest 76, 77. Initial experiments in equine 
chondrocytes indicated that 5-aza does up-regulate p21 (Figure 12 upper panel), although 
the response of human OA chondrocytes was less consistent (data not shown). Hwang 
and colleagues 78 demonstrated CDK6/cyclin D1/p21 complexes regulate type II collagen 
expression in articular chondrocytes and proliferative stimulation of articular 
chondrocytes in monolayer cultures compromises collagen type II expression. Therefore 
we investigated whether direct over-expression of p53 and p21, mimicking the 
downstream consequences of the DNA damage response were sufficient to mimic 5-aza 
effects in articular chondrocytes. 
In two independent experiments, p53 or p21 over-expression did not affect Col II 
expression by articular chondrocytes. Quantitative data from a Northern blot analysis are 
shown in Figure 12 (lower panel).   
 
DISCUSSION 
In this study we investigated the effects of the DNA methylation inhibitor, 5-
azacytidine, on the articular chondrocytic phenotype, with a specific focus on expression 
of the major extracellular matrix protein, collagen type II. Gene expression analyses 
demonstrated a significant increase in Col II expression following 5-aza exposure. Since 
collagen type II gene promoter and tissue-specific enhancer are encompassed in large 
CpG islands, we investigated whether the up-regulation of collagen type II expression 
observed in 5-aza treated chondrocytes was associated with changes in the methylation 
status of the promoter and/or enhancer sequences.  
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Initial analyses using methylation-sensitive restriction digestion followed by PCR 
amplification showed that the promoter and enhancer sequences contained very few 
methylated CpGs. This assay is an excellent screening assay since it is relatively 
inexpensive and rapid in comparison to other methods such as bisulfite conversion and 
sequencing. However, restriction-based techniques only evaluate CpGs that are contained 
within sites recognized by methylation-sensitive restriction enzymes. Some reports 
suggest that methylation changes in single CpG dinucleotides can activate expression of 
certain genes. Roach and co-workers have mapped the methylation status of MMPs-3, -9, 
and 13 and ADAMTS-4 promoters in human OA chondrocytes by methylation-sensitive 
restriction enzyme digestion and PCR. In all four enzyme sequences, the overall 
demethylation percentage was increased and some sites were preferably demethylated in 
OA samples 62. Similar results were obtained in subsequent gene-targeted analyses 63, 64. 
Similarly, Zimmermann et al 79 identified two adjacent CpGs that are differentially 
methylated in stem cells undergoing chondrogenesis, although the functional significance 
of this finding has not yet been established. 
Methylation-sensitive restriction analyses of the Col II promoter and enhancer did 
not identify any significant CpG methylation patterns that reflected the chondrocytic 
phenotype, differential collagen type II expression or 5-aza-mediated demethylation. 
Therefore, we performed bisulfite conversion and sequencing of the collagen type II 
promoter and enhancer to comprehensively assess CpG methylation across these regions. 
The bisulfite results confirmed the findings obtained by methylation-sensitive restriction 
analysis. Collectively, the analyses revealed that the collagen type II promoter and 
enhancer are predominantly unmethylated, and sporadic methylation sites are not 
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consistently located across individual samples. These results indicate that Col II 
expression is not directly regulated by DNA methylation. This finding agrees with the 
current understanding that most strong CpG islands remain unmethylated, independent of 
their expression status. The majority of tissue-specific CpG islands that are differentially 
methylated are associated with genes that are important during development. Recent 
genome-wide analyses have indicated that tissue-specific differential methylation that 
correlates with gene expression is more likely to be located within CpG island shores, 
rather than within the CpG islands themselves 74, 80, 81.  
Since 5-aza did not seem to directly upregulate collagen type II through direct de-
methylation of the promoter or enhancer, we investigated whether 5-aza also induced 
expression of other cartilage matrix genes. 5-aza up-regulated the expression of several 
other chondro-specific extracellular matrix genes; aggrecan, collagen types IX and XI, 
and link protein. Collagen type X, exclusively expressed by hypertrophic chondrocytes, 
was not upregulated, indicating that these cells did not undergo hypertrophy following 5-
aza treatment as previously suggested 57, 58, 66. It has already been established that the 
aggrecan promoter is not differentially methylated in articular chondrocytes 82, 
suggesting that these matrix genes are not individual targets of methylation-mediated 
regulation. 
Several transcription factors are known to regulate chondro-specific extracellular 
matrix genes. For instance, during chondrogenesis, transcription factors Sox-9, L-Sox-5 
and Sox-6 control the expression of several chondrocyte-specific genes such as Col II, 
aggrecan, Col XI and link protein 14-22 Also, Snail, Slug and Ids are transcription factors 
that have the ability to repress expression of the chondro-specific genes, Col II and Agg  
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75. Therefore a gene candidate approach was used to investigate the expression of some of 
these regulatory factors in articular chondrocytes following 5-aza treatment. None of the 
transcription factors studied showed any changes that would explain 5-aza effects on 
upregulation of multiple extracellular matrix chondro-specific genes. Therefore, we 
investigated whether 5-aza upregulated growth factors responsible for chondrogenesis 
and maintenance of the chondrocytic phenotype 4-7, 9, 68, 83-85. Quantitative PCR showed 
that TGF-β3 and its downstream regulator CTGF were significantly upregulated by 5-aza. 
Several studies indicate that TGF-β signaling is critical for joint formation and 
maintenance of articular cartilage 4-6, 85. TGF-β signaling is not only important for 
maintenance of healthy articular cartilage, but also has chondro-protective activities in 
OA, by counteracting the effects of inflammatory cytokines 86-89. Also, TGF-βs stimulate 
expression of tissue inhibitors of metalloproteases (TIMPs), and increase collagen type II 
and proteoglycan synthesis by osteoarthritic chondrocytes 90-93.  
The relative contributions of donor age and cartilage pathology to our results 
cannot be clearly distinguished since all donors were "elderly" and even relatively 
"normal" cartilage collected from the TJA specimens was undoubtedly influenced by the 
severe and chronic pathology present throughout the involved joints. However, there is a 
considerable body of evidence that aging per se plays a role in the dysregulation of 
growth factor signaling, leading to cartilage degradation and chondrocytic phenotype 
alterations 6, 93, 94. TGF-β2, TGF-β3 and TGF-β receptor expression is decreased in old 
mice 6. Corroborating this finding, TGF-β signaling deficiency, through targeted 
disruption of Smad3 5 or over-expression of a truncated, non-functional Tgfbr2 4  leads to 
articular cartilage changes that resemble osteoarthritis. Therefore, it is possible that TGF-
86 
 
β3 down-regulation by CpG methylation contributed to OA and the eventual need for 
joint replacement, and that 5-aza administration to OA chondrocytes relieved the 
methylation suppression of TGF-β3 gene, leading to increased expression of 
chondrocytic matrix genes observed in our study. At this juncture, TGF-β3 is a potential 
candidate for mediating the up-regulation of Col II and other cartilage matrix genes by 5-
aza. Additional studies will need to be completed to clarify this possibility. Without 
question, the advanced age of the donor population (60-90 years of age) provide ample 
time for cumulative stochastic methylation events to influence the expression of critical 
homeostatic genes in articular cartilage and other organs.   
The recent development of high throughput technologies (ChIP-chip and ChIP 
sequencing) 95, 96 have allowed researchers to identify and map epigenetic marks across 
the entire genome, to compare epigenetic features of specific regions between different 
tissues, and to associate epigenetic alterations with gene transcriptional states. These 
studies have greatly increased our understanding of DNA methylation profiles and 
associated effects on transcriptional activity. Most strong CpG islands promoters, such as 
the Col II island, are unmethylated independent of their gene expression profile; promoter 
hypomethylation and gene body methylation positively correlates with gene expression; 
promoters with few CpGs can be highly methylated and transcriptionally active; 
methylation of CpG island shores (regions of lower CpG density near (~2 kb) CpG 
islands) of promoter-associated CpG islands correlates with transcriptional inactivation; 
most tissue-specific DNA methylation is found in CpG island shores, rather than in CpG 
islands. Therefore it is unlikely the simple analyses of gene promoters using a gene 
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candidate approach will lead to the identification of regulatory regions in the genome that 
are influenced by CpG methylation and consequently responsive to 5-aza administration.  
5-aza exerts its effects on genomic methylation predominantly by functioning as a 
cytidine analog during DNA replication. However, there are other mechanisms by which 
5-aza might influence chondrocyte activity. The DNA/Dnmt adducts created by 5-aza 
incorporation triggers a DNA damage response resulting in p53 activation, increased 
p21Waf1/Cip1 expression, and cell cycle inhibition 76. Zhu et al, 2004 77 used deletion 
analyses and site-directed mutagenesis of the p21 promoter to demonstrate that 5-aza-
CdR induction of p21Waf1/Cip1 expression requires two p53 binding sites in the p21 
promoter. Comet assays and bisulfite sequencing were used to demonstrate that 5-aza-
CdR-induced p21Waf1/ Cip1 expression was dependent on DNA damage as opposed to 
DNA demethylation. 
Others have also demonstrated that 5-aza-CdR has replication-independent effects 
97-100. Firstly, 5-aza-CdR is able to induce Dnmt1 degradation through the proteosomal 
pathway 100. Secondly, Dnmt1 might control DNA methylation in a replication-
independent manner since it binds chromatin throughout G2 and M phases 99. Finally, 5-
aza can be incorporated into RNA, resulting in the inhibition of RNA and protein 
synthesis independently of any effect on the genome 97, 98.  
 In summary, 5-aza and its analogs can influence cellular systems through their 
ability to decrease global methylation in replication-dependent or –independent manners, 
through DNA damage response, or through inhibition of mRNA and protein synthesis. 
These alternative mechanisms are particularly pertinent to the actions of 5-aza in 
chondrocyte populations, since phenotypically stable chondrocyte culture models such as 
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the one used in these experiments (low/no serum-suspension/non-adherent) do not 
support sustained cell proliferation. Adenoviral over-expression studies indicated that p53 
or p21 overexpression in articular chondrocytes was not sufficient to up-regulate Col II or 
Agg gene expression, suggesting that DNA damage was not the mechanism mediating 
Col II up-regulation in response to 5-aza.  
Accepting the ‘process of elimination’ outcomes in this experimental series, our 
results strongly suggest that 5-aza positively influences the age- and/or OA-associated 
suppression of extracellular matrix genes critical for cartilage homeostasis.  Identification 
of the pathway(s) by which 5-aza exerts this activity could lead to therapeutic strategies 
to counter the cartilage matrix degradation that is the central pathological process in OA. 
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FIGURES AND TABLES 
Table 1. Primers utilized to generate Northern Blot probes 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Collagen type II  5’CCGAGGCAACGATGGTCAGC (822) 60°C 
(380 bp) 5’TGGGGCCTTGTTCACCTTTGA (1201)  
Aggrecan  5’TAGTGGAGCTACCCCAGTGC (5952) 58°C 
(671 bp) 5’GGCATATGACGTGTCCCTCT (6622)  
p21 5’CGTGAGCGATGGAACTT (211) 54°C 
(310 bp) 5’CTGTCATGCTGGTCTGC (520)  
EF1 α  5’AAAATGACCCACCAATGGAA (1051) 62°C 
(210 bp) 5’GCAGCATCACCAGACTTCAA (1261)  
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Table 2. Primers utilized in the qPCR reactions 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Collagen type I  5’AGCCAGCAGATCGAGAACAT (3841) 62°C 
(303 bp) 5’CGCCATACTCGAACTGGAAT (4144)  
Collagen type II 5’ATGACAATCTGGCTCCCAAC (4062) 62°C 
(220 bp) 5’CTTCAGGGCAGTGTACGTGA (4282)  
Collagen type IV 5’ATCGACAACCTGAGGGACAG (310) 62°C 
(193 bp) 5’TGATAGCGCAGTCGGTGTAG (502)  
Collagen type IX 5’GCAGGTGGCTTACAAGTTGG (395) 62°C 
(246 bp) 5’TGGAGACTTCCATCCAGTCC (640)  
Collagen type X 5’TGAGCAGCAACGTAAAAACG (2303) 62°C 
(225 bp) 5’AGGAAATGCCGAGTTTCTCA (2527)  
Collagen type XI 5’TGAGCATGGTATTCAGCAAA (678) 62°C 
(159 bp) 5’TTCTCCACGCTGATTGCTAC (836)  
Aggrecan 5’TGAGTCCTCAAGCCTCCTGT (6423) 62°C 
(200 bp) 5’GGCATATGACGTGTCCCTCT (6622)  
Link Protein 5’TGTTTCTGAAGGGAGGCAGT (452) 62°C 
(169 bp) 5’CCCAGTCGTGGAAAGTAAGG (620)  
COMP 5’GGAGATCGTGCAGACAATGA (1710) 62°C 
(152 bp) 5’AGCTGGAGCTGTCCTGGTAG (1861)  
CTGF 5’AGTGGGAGGGTACCAGCAGA (1466) 62°C 
(159 bp) 5’TTGATGGCTGGAGAATGCAC (1625)  
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Table 2. (cont.) 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
TGF-β1 5’ACCTGAACCCGTGTTGCTCT (1299) 62°C 
(225 bp) 5’AAGGCGAAAGCCCTCAATTT (1524)  
TGF-β2 5’CTGTCCCTGCTGCACTTTTG (856) 62°C 
(172 bp) 5’GCAGGAGATGTGGGGTCTTC (1028)  
TGF-3 5’CAAATTCAAAGGCGTGGACA (997) 62°C 
(242 bp) 5’CCCAGATCCTGTCGGAAGTC (1239)  
Sox-9 5’ATCAAGACGGAGCAGCTGAG (1561) 62°C 
(161 bp) 5’GAGCTGGAGTTCTGGTGGTC (1721)  
IGF-1 5’CACTGCAGGAGGGACTCTGA (6693) 62°C 
(151 bp) 5’GACATGGTATTTGGGGCCTTT (6843)  
p63 5’TCATGGATTTGGCACTAGCC (4353) 62°C 
(166 bp) 5’TTGAGCTGAGGCCACAAGAA (4518)  
BMP-2 5’CTTCAAAGGGGCTGATCTGG (2791) 62°C 
(242 bp) 5’AACAGAGGGTGGGCAGAAAA (3032)  
BMP-4 5’AAGCGTAGCCCTAAGCATCA (954) 62°C 
(187 bp) 5’TGGTTGAGTTGAGGTGGTCA (1140)  
BMP-6 5’TACCCTCCTCCCCCAAAAAC (1997) 62°C 
(233 bp) 5’TGTGCGTCCTGTGGACTTCT (2229)  
BMP-7 5’GCAGGCAAAACCTAGCAGGA (1634) 62°C 
(190 bp) 5’TTCGCACAGACACCAATGTG (1823)  
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Table 2. (cont.) 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Twist 5’GGAGTCCGCAGTCTTACGAG (644) 62°C 
(161 bp) 5’CCAGCTTGAGGGTCTGAATC (805)  
Slug 5’GAGCATACAGCCCCATCACT (811) 62°C 
(330 bp) 5’GCAGTGAGGGCAAGAAAAAG (1141)  
Snail 5’TTTACCTTCCAGCAGCCCTA (155) 62°C 
(414 bp) 5’CCAGGCTGAGGTATTCCTTG (569)  
ID-1 5’CGGATCTGAGGGAGAACAAG (656) 62°C 
(211 bp) 5’CTGAGAAGCACCAAACGTGA (867)  
ID-2 5’CGTGAGGTCCGTTAGGAAAA (201) 62°C 
(236 bp) 5’ATAGTGGGATGCGAGTCCAG (437)  
ID-3 5’ACTCAGCTTAGCCAGGTGGA (551) 62°C 
(166 bp) 5’AAGCTCCTTTTGTCGTTGGA (717)  
ID-4 5’ATGGGATGAGGAAATGCTTG (1882) 62°C 
(223 bp) 5’TGGAGGAAGGAAAGCAGAAA (2105)  
EF1 α  5’AAAATGACCCACCAATGGAA (1051) 62°C 
(210 bp) 5’GCAGCATCACCAGACTTCAA (1261)  
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Table 3. Primers utilized in the PCR reactions following restriction enzyme digestion 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Collagen type II  5’CAAAAGGAAGGTCTGTTTGGGG (-1205) 65.5°C 
(183 bp) 5’CAGAATTTCCCAGTCGGCC (-1022)  
Collagen type II  5’GGCCGACTGGGAAATTCTG (-1041) 66°C 
(410 bp) 5’CTGCGTTGAAGGCTTCCTCT (-631)  
Collagen type II  5’ATGTCTTTTCCGTCCTTGGTCT (-383) 62°C 
(318 bp) 5’GCTGGGCTGTAACCTGAACC (-65)  
Collagen type II  5’AGCGTGACTCCCAGAGAGG (-164) 62°C 
(149 bp) 5’CTTTCGAGGCTGGCGAACT (-15)  
Collagen type II  5’AGTTCGCCAGCCTCGAAAG (-34) 64°C 
(352 bp) 5’CTGAGGGACGCATGGAAAG (+318)  
Collagen type II  5’AGACGCTGGTGCTGCTGAC (+203) 66°C 
(214 bp) 5’CTGCGTGTCCTGTGCCTAAG (+417)  
Collagen type II  5’GGACACGCAGAAGTTCACCA (+407) 66°C 
(429 bp) 5’TTCTTTGTGGCCTGGGATTT (+836)  
Collagen type II  5’AAATCCCAGGCCACAAAGAA (+816) 60°C 
(419 bp) 5’CAACCGTAGCAATCGACCAG (+1235)  
Collagen type II  5’CTGGTCGATTGCTACGGTTG (+1215) 62°C 
(515 bp) 5’TATTCCTCAAATGCCCAGGA (+1730)  
Collagen type II  5’CCTGGGCATTTGAGGAATACA (+1711) 62°C 
(642 bp) 5’GTTTCAGCCCCATCTGGAAG (+2353)  
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Table 3. (cont.) 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Collagen type II  5’CCCTCATCTGCATTTCAGAGC (+2223) 62°C 
(345 bp) 5’TTCGGGGAACTGTTTTGCTT (+2568)  
Collagen type II  5’GCAAAACAGTTCCCCGAAAG (+2550) 62°C 
(169 bp) 5’CCTAGGTGTGGACGGAGGAG (+2719)  
Collagen type II  5’TCCTTTCTGGGGCAGTCATT (+2740) 62°C 
(207 bp) 5’GGGGGAAATGCTAGGAGAGG (+2947)  
Collagen type II  5’CCTAGCATTTCCCCCTCTCC (+2932) 66°C 
(549 bp) 5’TCCTCCAAGACTGCAGAGGAA (+3481)  
Cyclin D1 5’AGTAGCAGCGAGCAGCAGAGT (+68) 64°C 
(296 bp) 5’ACCTCCTTCTGCACACATTTGA (+364)  
H19 5’CACTCATGGAAAAGCCTGAGAA (-1115) 62°C 
(207 bp) 5’AGAGTTCACGGGTCCAATCAC (-908)  
 
101 
 
Table 4. Primers utilized in the PCR reactions following bisulfite conversion 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Col II  5’GTTTGGGGGGTAGGGGTTATTTTTG (-237) 60°C 
331 bp) 5’CCCTCATACAAAAAACCCTTAAAACAAAAA (+94)  
Col II  5’GTTTTAAGGGTTTTTTGTATGAGGG (-69) 60°C 
(394 bp) 5’CCCTAAAACAAAATCCTTAATTAACAAAAC (+463)  
Col II  5’GTTTAGGGGAGAGATTTTAATTT (+2267) 55°C 
(298 bp) 5’RAAAAACTATTTTACTTCACC (+2565)  
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Figure 1. The effect of methylation on the outcome of digestion by the methylation-
sensitive restriction enzymes HpaII and HhaI. In the absence of methylation, both 
enzymes cleave the template and no PCR amplicon is produced. Methylation impairs the 
restriction enzyme activity and a PCR product is generated from the intact DNA 
template. 
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Figure 2. Representation of the collagen type II promoter region. Bisulfite converted 
primer pairs are labeled as S1-AS1, S2-AS2, S3-AS3. The transcription factors rich area 
is highlighted in green. The bottom scheme shows the TATA-box in blue, the exons in 
orange and the CpGs dinucleotides in pink.  
 
 
 
 
 
 
104 
 
 
 
 
 
 
 
 
Figure 3. Northern blot gel image and quantitative representation of 8 different 
experiments measuring collagen type II expression in chondrocytes treated or not with 5-
aza for 4 days. 5-aza significantly increased Col II mRNA levels. Student’s t-test p= 
0.0049.  
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Figure 4. Northern Blot gel image of collagen type II expression in chondrocyte 
monolayer cultures treated or not with 5-aza for 15 days. 5-aza supported Col II mRNA 
expression in culture conditions known to induce phenotypic de-differentiation and loss 
of Col II expression, as in the control (Cx) group above.  
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Figure 5. Northern blot of aggrecan expression in chondrocytes treated or not with 5-aza 
for 4 days (inset) and quantitative representation of 8 different experiments assessing the 
expression of collagen types II, IX, XI, VI, I, X, aggrecan (Agg), link protein (LP) and 
cartilage oligomeric matrix protein (COMP) expression in chondrocytes treated or not 
with 5-aza for 4 days. 5-aza significantly increased aggrecan (p= 0.0014) and other 
chondro-specific extracellular matrix genes such as collagen type IX (p= 0.0091) and XI 
(0.0183), and link protein (p= 0.0403).     
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Figure 6. The methylation status of the collagen type II promoter by methylation-
sensitive restriction enzyme digestion followed by PCR amplification in the 
chondrogenic cell lines HTB94, TC-28a4, osteogenic cell lines SAOS-2, U2OS and HeLa 
cells.  The methylation status of the collagen type II promoter varies among different cell 
lines and the methylation patterns do not reflect phenotypic background or Col II 
expression.  
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Figure 7. The methylation status of the collagen type II promoter in cartilage and bone 
from different human donors in P1 and P12 monolayer cultures.  Methylation of CpG 
sites was identified by methylation-sensitive restriction enzyme digestion followed by 
PCR amplification The methylation status of the collagen type II promoter varies within 
each tissue type and between the different tissues without consistent differences being 
apparent. The Col II promoter methylation status did not change during 12 monolayer 
passages, generating de-differentiated ‘chondrocytes’ that do not express collagen type II.  
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Figure 8. The methylation status of the collagen type II promoter in articular 
chondrocytes and HeLa cells treated with 5-aza for 4 days. The methylation status was 
determined by methylation sensitive restriction enzyme digestion followed by PCR 
amplification. The methylation profiles of the collagen type II promoter was not affected 
by 5-aza treatment. 
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Figure 9. Identification of methylated CpGs in the Col II enhancer by bisulfite 
conversion followed by PCR. DNA from 6 different donors was used for bisulfite 
conversion. Six clones from each individual were sequenced. Open circles represent an 
unmethylated cytidine at a CpG site and dark circles represent a methylated cytidine at a 
CpG site. Methylated CpGs in the Sox-9 enhancer region are infrequent and sporadic, 
inconsistent with a gene regulated by methylation.  
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Figure 10. Effect of 5-aza administration on the expression of transcription factors that 
regulate the chondrocytic phenotype.  Sox-9, p63, twisted gastrulation (TW), slug (Sl) 
and inhibitor of differentiation (Id) 1-4 in chondrocytes treated or not with 5-aza for 4 
days. The expression of Sox-9 and p63, factors that trans-activate the Col II gene, were 
not up-regulated by 5-aza treatment. Further, the expression of transcriptional repressors 
such as twisted gastrulation, Slug, and Ids 1-4 were not affected by 5-aza. In fact, Ids 1, 
2, and 4 were significantly upregulated (p= 0.0364; 0.0455; 0.0447, respectively). 
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Figure 11. Effect of 5-aza administration on the expression of growth factors known to 
support the chondrocytic phenotype. Expression of TGF-βs 1-3, connective tissue growth 
factor (CTGF), BMPs 2, 4, 6 and 7, and Insulin growth factor 1 (IGF1) in chondrocytes 
treated with 5-aza for 4 days was assessed by qPCR. Expression of TGF-β 3 (p= 0.0068) 
and CTGF (p= 0.0073) was significantly increased, whereas IGF1 expression was 
significantly down-regulated (p= 0.0102). 
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Figure 12. Upper panel. 5aza dose-dependently stimulates p21 expression in equine 
articular chondrocytes. p21 expression was assessed by Northern blotting.  
Lower panel.  Collagen type II expression by human articular chondrocytes treated with 
5-aza or infected with adenoviral plasmids expressing p53, p21 or Lac Z (2, 10 or 25 
infectious particles per cell). Col II mRNA expression was assessed by Northern blotting. 
Adenoviral over-expression of p21 or p53 did not increase steady levels of Col II mRNA 
in articular chondrocytes. 
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CHAPTER 4: COLLAGEN TYPE X EXPRESSION AND 5’ CpG 
METHYLATION STATUS IN OSTEOARTHRITIC ARTICULAR 
CHONDROCYTES 
 
INTRODUCTION 
 Osteoarthritis (OA) is the most prevalent age-related disease in the world. The 
degeneration of articular cartilage that occurs in OA is progressive and irreversible; 
current treatments, with the exception of total joint arthroplasty, are predominantly 
palliative. OA affects over 60% of the US population over 65 years of age 1 and 
associated health costs amount to more than 60 billion dollars per year to the United 
States economy alone 2, 3. OA is characterized by progressive articular cartilage matrix 
depletion, fibrillation and loss 4, deep matrix calcification 5, and subchondral bone 
alterations 6. Several pro-inflammatory cytokines involved in OA pathogenesis impact 
cartilage homeostasis 2. In particular, interleukin (IL)-1β, IL-6 and soluble IL-6 receptor 
have been directly implicated in the down-regulation of collagen type II (Col II) during 
OA. These cytokines suppress Col II expression by increasing Sp3 occupancy in the 
promoter region of the Col II gene 7, 8. In addition, these cytokines stimulate the release 
of degradative enzymes such as matrix metalloproteases (MMP-2, -3, -8, -13), 
aggrecanases 1 and 2 (ADAMTS 4 and 5) and cathepsins, and suppress the synthesis of 
inhibitors such as the tissue inhibitors of metalloproteases (TIMPs). The change in matrix 
constitution and imbalance in synthesis: degradation ratio account for the cartilage 
destruction observed in OA 4, 9.   
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 In addition to loss of extracellular matrix homeostasis, OA has also been linked to 
phenotypic alterations of the resident chondrocytes. Aberrant chondrocyte proliferation 
results in formation of cell clusters, or ‘chondrons’ and chondrocytes undergo phenotypic 
changes resembling the transitions that occur during hypertrophy. OA chondrocytes 
express collagens type I, IIA, III, and X, in addition to collagens IIB, VI, IX and XI that 
are usually expressed by normal chondrocytes 10-12. These alterations have been 
demonstrated by comparative microarray analyses 13 and by differential immunostaining 
in OA and normal cartilage 14. Therefore, dysregulation of mechanisms involved in 
articular chondrocyte phenotypic stability are implicated in the pathogenesis of 
osteoarthritis.    
Epigenetics refers to “heritable changes in gene expression that occur without 
changes in DNA sequence” 15. Epigenetics impact gene regulation though DNA 
methylation, histone protein modifications and chromatin organization. Overall, DNA 
methylation of CpG islands is associated with histone hypoacetylation and transcriptional 
repression. DNA methyltransferases incorporate a methyl residue to cytidines within 
CpG dinucleotide sequences. This modification can impair transcription by several 
means. Firstly, it can interfere with the recognition of DNA binding sites by transcription 
factors and other DNA binding proteins. Secondly, methylation can recruit CpG methyl-
binding proteins impeding transcription factor binding. Lastly, methyl-CpG binding 
proteins can recruit histone deacetylases (HDACs), histone methyltransferases (HMTs) 
and chromatin-remodeling factors. These modifications condense chromatin structure, 
hiding potential binding sites for transcriptional activators and restricting occupancy. As 
a consequence, transcription is repressed 16. However, promoter occupancy does not 
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depend solely in its epigenetic state. Transcriptional activation and repression are also 
regulated by competitive binding of promoter, enhancer and silencer elements 7, 8, 17-20. 
Therefore, activation or repression of a gene is a collective consequence of the interplay 
of transcription factors and epigenetic constraints.   
Epigenetic processes are involved in regulation of germline-specific genes, tissue-
specific genes, imprinting, and aging 21. A growing body of work indicates that 
epigenetics are also critical in a range of disease processes. Cancer cells are globally 
hypomethylated, although specific tumor suppressor genes are hypermethylated and 
transcriptionally suppressed 22. Moreover, increased CpG methylation in CpG islands and 
concurrent loss of CpG methylation beyond island sequences is correlated with aging 23. 
Environmental factors such as tobacco consumption, carcinogen exposure and diet also 
influence methylation profile and might predispose to certain diseases 24. Several recent 
studies have demonstrated the importance of epigenetic gene regulation in chondrocyte 
development and homeostasis. HDAC4 functions as a negative regulator of chondrocyte 
hypertrophic differentiation by suppressing the activities of Runx2, a transcription factor 
required for hypertrophy25. HDAC activity is also necessary to support collagen type II 
expression in articular chondrocytes, and facilitate re-differentiation of (monolayer) de-
differentiated chondrocytes 26. The DNA methyltransferase inhibitor, 5-azacytidine (5-
aza), induced expression of hypertrophic markers in phenotypically stable, chick articular 
chondrocytes 27, suggesting that DNA methylation influences lineage commitment in 
chondrocyte populations. Cheung and colleagues 28 observed similar results when 
treating bovine fetal epiphyseal chondrocytes with 5-aza. 
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Epigenetics is also critical to the pathogenesis of OA. Young et al. (2005) 
29utilized a bovine nasal cartilage explant model to induce cartilage matrix degradation 
with IL-1α and oncostatin M. Explants co-treated with HDAC inhibitors (trichostatin A 
or sodium butyrate) had decreased cartilage matrix degradation by blocking the induction 
of MMPs 1 and 13 and ADAMTS 4, 5 and 9 mRNA expression. Moreover, Roach et al 
(2005) 30, linked osteoarthritic changes in articular chondrocyte to CpG methylation 
alterations in the promoter sequences of MMPs-3, 9, 13 and ADAMTS-4 31 that result in 
epigenetic de-silencing of these enzymes in OA. More recently, Zimmermann et al. 
(2008) 32 identified two CpG dinucleotides in the collagen type X promoter that were 
methylated in uncommitted mesenchymal stem cells but became de-methylated during in 
vitro chondrogenesis. The de-methylation of these CpGs correlated with collagen type X 
expression.  
Given that osteoarthritic chondrocytes undergo phenotypic changes characteristic 
of hypertrophic chondrocytes and aberrantly express collagen type X, the objective of 
this study was to determine whether the methylation status of the CpG dinucleotide 
identified by Zimmermann et al. (2008) 32 in the context of stem cell chondrogenesis is 
also linked to collagen type X expression in osteoarthritic chondrocytes. The study 
addressed the hypothesis that induction of collagen type X expression in osteoarthritic 
articular chondrocytes is related to demethylation of cytidines positioned 1,680 and 1,674 
bases 5’ to the collagen type X start site. 
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METHODS 
Sample collection 
Human articular cartilage was harvested from 11 osteochondral tissue specimens 
retrieved from total joint arthroplasty (TJA) procedures obtained from Carle Clinic in 
Urbana, IL following total knee replacement procedures. Articular cartilage was obtained 
from 3 women (60-79 years) and from 8 men (59-86 years). In addition, a bone sample 
was collected from a female donor (90 years) for use as a control. This project was 
approved by both the University of Illinois Ethics Committee and the Carle Clinics Ethics 
Committee. Informed consent was obtained from the patients before surgery.   
The articular cartilage specimens presented with variable degrees of arthritic 
change, both between and within specimens. Therefore, articular cartilage was 
categorized according to macroscopic characteristics; samples that were not fibrillated 
were considered ‘normal’, whereas cartilage samples with surface fissures or fibrillation 
were considered to be ‘osteoarthritic’. Severely degenerative tissues and osteophytic 
cartilage were excluded. Cancellous bone was harvested from the central region of the 
proximal tibial fragment. The cartilage and bone were snap frozen in liquid nitrogen and 
stored at -80°C for until needed for RNA and DNA isolation. 
 
RNA extraction 
The articular cartilage samples were pulverized under liquid nitrogen in a Spex 
6700 Freezer/Mill (Spex Industries Inc., Metuchen, NJ, USA). Approximately 200 mg of 
pulverized cartilage was saved for DNA extraction and stored at -20°C. Total RNA was 
extracted from articular cartilage using previously described protocols 33. Briefly,  2-3 g 
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of powdered cartilage was mixed with 8 mL of guanidinium isothiocyanate lysis buffer 
(4M Guanidinium thiocyanate (Fisher Scientific, Philadelphia, PA, USA), 100mM Tris-
HCl (Fisher Scientific) and 25 mM EDTA (Fisher Scientific), 80 µL of β-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO) and homogenized in a Ultra-Turrax 
T25 homogeneizer (Janke & Kunkel, IKA-Labortechnik, Staufen, Germany) for 2 
minutes. The sample was placed on ice and 650 µL of 25% Triton X-100 (Sigma-Aldrich 
Corporate) was added to the samples. After 10 minutes on ice, the sample was 
centrifuged at 805 rcf for 5 minutes in a refrigerated centrifuge (Centrifuge 5810 R, 
Eppendorf, Westbury, NY). The supernatant was transferred to an ultracentrifuge tube 
(Beckman Coulter Inc.), 8 mL of 3 M sodium acetate was added and the sample was 
mixed. Thirteen milliliters of water-saturated phenol (Fisher Scientific) and 3 mL of 
chloroform: isoamyl alcohol (Fisher Scientific) (49:1) were added, the sample was well 
mixed and placed on ice for 10 minutes.  The aqueous and organic phases were separated 
by centrifugation (48,394 rcf for 30 minutes) in an ultracentrifuge (Beckman Coulter 
Inc.). Phenol: chloroform (1:1) extraction was repeated until the insoluble debris 
separating aqueous and organic phases was minimal. The aqueous phase was transferred 
to an ultracentrifuge tube (Beckman Coulter Inc), 13 mL of isopropanol (Fisher 
Scientific) was added and the sample was kept at -20°C overnight to facilitate RNA 
precipitation. RNA was pelleted by centrifugation at 72,128 rcf for 30 minutes. The pellet 
was transferred to a 1.5 mL microcentrifuge tube (Fisher Scientific) and washed with 
70% ethanol (PHARMCO_AAPER, Shelbyville, KY) in diethyl pyrocarbonate (Sigma-
Aldrich) (DEPC)-treated water. Proteoglycans co-precipitated with the RNA were 
removed using the RNeasy “clean up” protocol (Qiagen, Valencia, CA). Briefly, the 
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pellet was dissolved in 600 µL of Lysis Buffer RLT and mixed with 900 µL of 70% 
ethanol. The mixed solution was applied to the RNeasy column and spun at 8,100 rcf for 
15 s (Denville 260D centrifuge – Denville Scientific Inc., Metuchen, NJ, USA). The 
column was rinsed with 400 µL of Wash Buffer RW1, and 80 µL of DNase I in RDD 
Buffer (Qiagen) was applied to the column. After 15 minutes at room temperature, the 
column was washed with 400 µL of RW1, followed by two 500 µL washes with Wash 
Buffer RPE. The column was dried by centrifugation at 8,100 rcf for 2 minutes and then 
the RNA was eluted with 55 µL of RNase free water. 
 
Reverse transcription reaction 
First strand cDNA was synthesized by reverse transcription using First Strand 
cDNA Superscript II (Invitrogen Corporation, Carlsbad, CA) and Oligo dT as per 
manufacturer’s instructions. Briefly, one microgram of total RNA was brought up to 10 
µL and then combined with 1 µL of oligo (dT) (0.5µg/µL) and 1 µL of 10 mM dNTPs. 
The sample was incubated in a 65°C water bath for 5 minutes and then placed on ice for 1 
minute to denature the RNA and allow binding of the oligonucleotides.  The following 
reagents were added: 2 µL 10x First Strand Buffer, 2 µL 0.1M DTT, 2 µL 50 mM MgCl2 
and 1 µL RNase out. After a gentle mix and brief centrifugation, the sample was 
incubated at 42°C water bath for 2 minutes, 1 µL (50 units) of SuperScript II Reverse 
Transcriptase was added. The sample was then incubated at 42°C for 50 minutes. The 
reaction was stopped by placing the sample in a 70°C water bath for 15 minutes.  The RT 
reactions were diluted (1:10 ratio) with water and stored at -20°C until further use. 
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Quantitative PCR 
Quantitative PCR (qPCR) was used to assess collagens type II and type X, 
aggrecan and alkaline phosphatase gene expression profiles in the cartilage samples. The 
PCR reactions were carried out in a final volume of 25 µL.  The 2x SYBR Green 
Supermix (Bio-Rad Laboratories, Hercules, CA) was used for these reactions. This 
reagent contains  100 nM KCl, 40 mM Tris-HCl, 0.4 mM of each dNTP, 50 units/mL of 
Taq polymerase, 6 mM MgCl2, and 20 nM SYBR Green I.  The SYBR Green Supermix 
(12.5 µL) was added to 1 µL of the sense (10 pMol) and 1 µL of the antisense primers.  
Autoclaved distilled water (5.5 µL) and 5 µL of cDNA template were also added. The 
initial denaturation step was carried out at 95°C for 3 minutes, then 45 cycles of 
denaturation at 95°C for 10s, annealing temperature of 62°C for 30s and polymerase 
extension at 72°C for 20s followed. The samples were denatured at 95°C for 1 min before 
starting the melting curve protocol that consisted of decreasing the temperature at 55°C 
for 1 minute followed by increments of 0.5°C every 10 s till 95°C was reached. The 
primer combinations used in these experiments were designed for annealing at 60-62°C, 
however optimal annealing temperatures were determined by temperature gradient 
analyses spanning 54-64°C. The specificity of the PCR products was monitored by 
melting curve analyses, PCR fragment cloning and sequencing.  Graphs showing the 
fluorescence intensity were plotted for each cycle.  Quantitative results were accessed 
using the cycle threshold determined to represent the onset of the linear phase of 
amplification, as calculated by the thermal iCycler software (Bio-Rad). To assess 
potential contamination, water was used as negative control for each on the reactions 
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instead of cDNA. The qPCR data was normalized by the elongation factor-1 alpha 
(EF1α) expression. The primers are listed in Table 5. 
  
DNA extraction 
 Approximately 200 mg of powdered cartilage or bone was digested overnight at 
50°C using 2 mL of proteinase K digestion buffer (100 mM NaCl, 10 mM Tris-HCl (pH 
8.0), 25 mM EDTA (pH 8.0), 0.5% SDS and 0.1 mg/mL of proteinase K). The DNA was 
extracted in 1 mL of phenol and 1 mL of chloroform: isoamyl alcohol (24:1). After 
vortexing, the sample was centrifuged at 8,100 rcf for 10 minutes in a bench top 
centrifuge (Denville 260 D, Denville Scientific Inc., Metuchen, NJ) to separate the 
organic and aqueous phases. The aqueous supernatant was transferred to a new 
microcentrifuge tube and 500 µL of 7.5 M ammonium acetate and 2 mL of 100% ethanol 
were added. The sample was mixed by inversion of the tube and allowed to precipitate at 
room temperature for 5 minutes before being span at 8,100 rcf for 2 minutes. The 
supernatant was discarded and the pellet was washed with 70% ethanol, air dried and 
reconstituted in 270 µL of TE buffer. The sample was re-precipitated overnight at -20°C 
using 30 µL of 3 M Na acetate and 900 µL of 100% ethanol. The sample was pelleted at 
8,100 rcf for 10 minutes, washed in 70% ethanol, air dried, resuspended in 200 µL of TE 
buffer and quantified by UV spectrophotometry. The sample was stored at -20°C until 
needed.  
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Methylation-sensitive restriction enzyme digestion  
 As reported by Zimmermann et al. (2008) 32, the cytidines located at position -
1,680 and -1,674 upstream of the transcription start site of the collagen type X gene were 
>50% demethylated during chondrogenesis and the degree of methylation correlated with 
collagen type X expression during mesenchymal stem cell differentiation. These sites 
(ACGT) are recognized by the methylation-sensitive restriction enzyme HpyCH4IV. To 
determine whether collagen type X expression by human osteoarthritic chondrocytes 
correlates with demethylation of these cytidines, primers spanning these putative 
restriction sites were designed.  
Sufficient DNA was able to be extracted from ten of the initial 15 human OA 
cartilage samples for CpG methylation analysis. Five hundred nanograms of genomic 
DNA extracted from articular cartilage, were digested or not (control) with HpyCH4IV 
(New England Biolabs, Ipswich, MA) in a 40 µL reaction at 37°C overnight. EcoRV 
(Invitrogen) was also added to both control- and HpyCH4IV-digested samples to reduce 
the fragment size of the genomic templates. Twenty units of both enzymes were added to 
the digestion buffers to ensure complete digestion of the genomic DNA. Primers 
spanning an HpyCH41V cleavage site in the collagen type II promoter were used to 
assess complete DNA digestion, given that previous studies have shown that the collagen 
type II promoter is predominantly unmethylated in chondrocytes. The restriction 
digestion was stopped by heating the samples at 65°C for 25 minutes. The samples were 
diluted with 40 µL of water. 
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PCR amplification 
 Five microliters of the diluted samples (31.25 ng DNA) were used as templates 
for PCR reactions. The PCR reaction (25 µL) contained 2.5 µL of 10x PCR buffer 
(Invitrogen), 1 µL of 50 mM MgCl2, 0.5 µL of 10 mM dNTPs (Invitrogen), 10 pMol of 
the sense primer, 10 pMol of the antisense primer and 0.3 µL of Taq DNA polymerase 
(Invitrogen), in addition to the DNA template. The protocol for the PCR reaction was as 
follows: 95°C denaturation for 5 minutes, 25 cycles at 95°C for 30 s, 62°C for 30s, 72°C 
for 20s, 1 cycle at 72°C for 10 min and 4°C indefinitely. PCR products were separated by 
electrophoresis using a 2 % agarose TAE gel. The primers are listed in Table 6. 
 
Band quantification 
The 2% agarose TAE gel was stained with ethidium bromide and photographed 
using a Kodak EDAS 290 system (Carestream Health, Inc., Rochester, NY) for band 
intensity comparison between control and samples digested with HpyCH4IV (Figure 13).  
Band intensity was quantitatively analyzed by using ImageJ software (free download 
available at http://rsbweb.nih.gov/ij/). 
 
Statistical analysis 
 Statistical analyses were carried out using GraphPad Prism version 3.0 software.  
Differences in the expression of collagen type X mRNA and in the extent of CpG 
demethylation between grossly normal and OA cartilage specimens were analyzed by 
Student’s t- tests. Correlations between Collagen type X and ALP expression, and 
between demethylation and collagen type X expression and were determined by 
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Pearson’s correlation coefficient. For all analyses, p values of < 0.05 were considered to 
be significant.   
 
RESULTS 
There was a greater than 400-fold range in the levels of collagen type II mRNA 
expression although two samples were responsible for this considerable variation. 
Discounting specimens 3 and 4 (Figure 14), collagen type II expression showed 
approximately five-fold variation in the remaining 13 samples. Aggrecan mRNA 
expression showed similarly restricted variation across the samples. Interestingly, there 
were no obvious differences in collagen type II or aggrecan expression between the 
grossly ‘normal’ and ‘OA’ specimens.    
Collagen type X expression in the articular cartilage samples showed over 600-
fold variation between specimens (Figure 15), indicative of considerable phenotypic 
alterations in these cases. Collagen type X expression levels in grossly ‘normal’ and 
‘osteoarthritic (OA)” specimens were not significantly different (p value = 0.98). ALP 
expression was assessed as an independent marker of the hypertrophic phenotype. ALP 
expression was also highly variable and was correlated to Col X expression (Figure 16; p 
= 0.0343) in samples that presented higher Col X expression (greater than ‘100 fold’ in 
Figure 15; Pearson r = 0.5886; R2 = 0.3464). 
Cleavage activity of the methyl-sensitive restriction enzyme HpyCH4IV was used 
to assess the methylation status of cytidines located at position -1,680 and -1,674 
upstream of the transcription start site of the collagen type X gene. To test for complete 
DNA digestion by the enzyme HpyCH4IV, we used primers that spanned an HpyCH4IV 
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site in the collagen type II promoter (Figure 17). Previous studies demonstrated that this 
region of the collagen type II promoter is predominantly unmethylated in chondrocytes 
(see Chapter 3). As demonstrated in Figure 17, HpyCH41V digestion was complete in all 
cases. Demethylation of the targeted cytidines varied among individuals and among 
different samples from the same individual (Figure 18), but the level of demethylation, in 
general, was low among all the samples studied (between 4 and 12%). Of note, the extent 
of CpG demethylation in a single non-collagen type X-expressing bone specimen 
(8.49%) was comparable to the levels detected in the OA cartilage samples (Figure 18). 
There was no significant difference in ‘% CpG demethylation’ between grossly normal 
and OA specimens (p = 0.34). Further, there was no correlation between % demethylation 
and collagen type X expression (Pearson r = -0.1452; R2 = 0.02107; Figure 19). In 
essence, the targeted cytidines in the collagen type X promoter are highly methylated 
(greater than 88%) independent of collagen type X expression level.     
 
DISCUSSION 
This study was conducted to determine whether collagen type X expression in 
osteoarthritic chondrocytes is related to demethylation of the cytidines at position -1,680 
and -1,674 upstream of the transcription start site of the collagen type X gene. In the 
context of this investigation, we also assessed the expression of genes that characterize 
the chondrocyte phenotype (Collagen type II and aggrecan) 4, 34 and the expression of 
ALP; an independent marker of the hypertrophic phenotype 35, 36. As expected, aggrecan 
and collagen type II mRNAs were detected in all specimens; however, there was a 
broader range of Col II expression among samples, probably reflecting differing degrees 
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of degenerative pathology 37. Collagen type X mRNA expression varied considerably 
(approximately 600-fold variation) although in all OA specimens. ALP expression was 
correlated with collagen type X expression, consistent with several previous studies 5, 14, 
36, 38-40and indicating that these transcriptional alterations reflect a phenotypic change as 
opposed to an effect on a single gene.  
Our results do not support the hypothesis that induction of collagen type X 
expression in osteoarthritic articular chondrocytes is related to demethylation of the -
1,680 and -1,674 cytidines, as reported by Zimmermann et al. (2008). In the absence of 
an appropriate methylation-resistant isoschizomer as a control for complete digestion, we 
used primers spanning a region of the collagen type II promoter, which contains an 
HpyCH4IV restriction site and that we have identified as being unmethylated in 
chondrocytes, to control for complete digestion. In contrast to the results reported by 
Zimmermann et al, where demethylation of the -1,680 and -1,674 cytidine bases 
exceeded 50% in collagen type X-expressing chondrogenic MSCs. In our study, there 
was highly variable expression of collagen type X by human articular chondrocytes, but 
very little demethylation of the targeted CpG sites. The lack of correlation in the current 
study might be a consequence of phenotypic heterogeneity in the chondrocyte 
populations under examination; a relatively small number of cells could be responsible 
for overall collagen type X expression yet make minimal contributions to the methylation 
analyses of the targeted CpG sites. Accepting this possibility, the in vitro chondrogenesis 
model used in Zimmermann et al’s study also generates a phenotypically heterogeneous 
population within the three-dimensional pellet cultures, and so would also be subject to 
similar variations.  
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It is also possible that the regulation of collagen type X expression by 
differentiated chondrocytes differs from regulatory mechanisms in stem cells undergoing 
chondrogenesis and is not dependent on the methylation status of the targeted CpG sites. 
Self-evidently, a statistical correlation does not indicate any causal or functional 
association. Stem cells genomes are highly methylated, in comparison to those of 
differentiated cell populations, and that there is a decrease in overall methylation during 
differentiation 41. Therefore, the demethylation of the CpG sites observed by Zimmerman 
and colleagues could reflect a non-specific genome-wide demethylation during 
chondrogenic differentiation. Further, the genomic sequence surrounding the targeted 
CpG sites do not correspond to a recognized transcription binding site and the targeted 
CpG pairs are not conserved in murine or equine genomes, arguing against an important 
functional activity.  Transcriptional activation and repression are regulated by 
competitive binding of promoter, enhancer and silencer elements 7, 8, 17-20, independently 
of any epigenetic influences. 
In summary, collagen type X expression by human osteoarthritic chondrocytes is 
not linked to the methylation status of the of cytidines located at position -1,680 and -
1,674 upstream of the transcription start site of the collagen type X gene. 
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TABLES AND FIGURES 
Table 5. Gene specific primers utilized in the qPCR reactions. 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Collagen type II  5’ ATGACAATCTGGCTCCCAAC (+4062) 62°C 
(220 bp) 5’ CTTCAGGGCAGTGTACGTGA (+4282)  
Collagen type X  5’ TGAGCAGCAACGTAAAAACG (+2303) 62°C 
(225 bp) 5’ AGGAAATGCCGAGTTTCTCA (+2527)  
Aggrecan 5’ TGAGTCCTCAAGCCTCCTGT (+6423) 62°C 
(200 bp) 5’ GGCATATGACGTGTCCCTCT (+6622)  
ALP 5’ CCACGTCTTCACATTTGGTG (+1359) 62°C 
(195 bp) 5’ AGACTGCGCCTGGTAGTTGT (+1554)  
EF1 α  5’ AAAATGACCCACCAATGGAA (+1051) 62°C 
(210 bp) 5’ GCAGCATCACCAGACTTCAA (+1261)  
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Table 6. Primers utilized in the PCR reactions following restriction enzyme digestion 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Collagen type II  5’ CCTAGCATTTCCCCCTCTCC (+2932) 64°C 
(549 bp) 5’ TCCTCCAAGACTGCAGAGGAA (+3481)  
Collagen type X 5’ TTGTTGCAATAGCCACAGATG (-1763) 64°C 
(240 bp) 5’ TGGATGCTTTTGAATGCTAGG (-1523)  
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Figure 13. Restriction digestion analysis of Collagen type X promoter methylation. The 
methylation-sensitive restriction enzyme HpyCH4IV cuts unmethylated DNA templates 
but is unable to cleave methylated templates. As a consequence, PCR amplification of 
unmethylated DNA with primers that span the putative cleavage sites will be 
unsuccessful (at left) whereas methylated DNA will remain intact and support PCR 
amplification (at right).  
 
Cuts unmethylated 
A/CGT 
TGC/A 
AmCGT 
TGCmA 
PCR amplification 
 BAND NO BAND 
Can’t cut when methylated 
HpyCH4IV 
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Figure 14. Collagen type II (Coll II; above) and aggrecan (Agg; below) mRNA 
expression in 15 articular cartilage specimens collected from 11 TJA patients. mRNA 
levels were measured by quantitative PCR, normalized to EF1a mRNA levels and 
presented as ‘fold increases’ above expression in the normal cartilage sample from 
patient #4.  
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Figure 15. Collagen type X (Col X) mRNA expression in 15 articular cartilage 
specimens collected from 11 TJA patients. Collagen type X mRNA levels were measured 
by quantitative PCR, normalized to EF1α mRNA levels and presented as ‘fold increases’ 
above expression in the normal cartilage sample from patient #4. Note variation in 
collagen type X expression among individuals and within different areas from the same 
individual. 
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Figure 16. Relationship between collagen type X (Col X) mRNA expression and alkaline 
phosphatase (ALP) mRNA expression. Notice the broad expression ranges of both genes 
and the strong correlation between Col X and ALP expression (p = 0.0343) in samples 
with Col X mRNA expression greater than 100 times the reference value (Pearson r = 
0.5886; R2 = 0.3464).  
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Figure 17. Gel image of Col X promoter amplicons generated from methylation-sensitive 
restriction enzyme digestion followed by PCR amplification. Lane A samples were 
digested with EcoRV. Lane B samples were digested with EcoRV and HpyCH4IV. Col II 
was used as a control for complete digestion.  The differences in intensities between Col 
X ‘A’ and ‘B’ bands reflect variations in the amount of methylation among individuals 
and among different samples from the same individual.  
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Figure 18. Col X CpG demethylation based on quantification of band intensity after 
methylation-sensitive restriction enzyme digestion followed by PCR amplification 
approach. Notice that there is variation of amount of demethylation among individuals 
and among different samples from the same individual, but the level of demethylation, in 
general, was low among all the samples studied (below 12%). 
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Figure 19. The correlation between fold change in Col X mRNA expression and the level 
of demethylation in the same samples. The level of Col X mRNA expression is not 
correlated with the level of demethylation of the samples (Pearson r = -0.1452; R2 = 
0.02107).  
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CHAPTER 5: DIFFERENTIAL PHENOTYPIC EFFECTS OF 5-AZACYTIDINE 
ON ARTICULAR AND ENDOCHONDRAL CHONDROCYTE POPULATIONS 
 
INTRODUCTION 
Cartilage is a highly specialized avascular and aneural connective tissue 
characterized by a small number of cells, termed chondrocytes, interspersed within a 
large volume of extracellular matrix. Cartilage exists as a temporary tissue in cartilage 
anlagen during skeletal development, in the growth plates and epiphyses of growing bone 
and in fracture callus 1-3. In these cases, the transient cartilage template is replaced by 
bone during the process of endochondral ossification. Collectively, signaling pathways 
mediated by the secreted ligands parathyroid hormone-related peptide (PTHrP), fibroblast 
growth factors (FGF), Indian hedgehog (Ihh), transforming growth factor beta (TGF-β), 
bone morphogenetic proteins (BMP), and Wnts interact to drive chondrocyte 
proliferation and to control the transition of chondrocytes into the hypertrophic phase of 
differentiation 4-7. Hypertrophic chondrocytes undergo marked increases in cellular 
volume and length and express several phenotype-specific genes; in articular, collagen 
type X (Col X) and alkaline phosphatase (ALP). Terminally, hypertrophic chondrocytes 
undergo apoptosis and the hypertrophic cartilage matrix is colonized by vascular 
endothelial cells and osteoblast precursors 4, 7.  
In contrast to the cartilaginous tissues engaged in bone formation, permanent 
cartilage is found in several parts of the body and is categorized into three types 
depending on differences in extracellular matrix composition. Elastic cartilage is rich in 
elastin and it is found in the ear pinna, epiglottis and larynx. Fibrocartilage contains 
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comparatively high levels of collagen type I and is located in intervertebral discs, 
meniscus, compressive sites within tendons and the pubic symphysis. Hyaline cartilage is 
rich in collagen type II (Col II) and proteoglycans and is located in the rib cage, nose, 
larynx, trachea, and bronchi, and on the articular surfaces of bones.   
Articular cartilage is a highly specialized tissue that covers the articulating 
surfaces of bones. It is a hypocellular, avascular tissue, rich in extracellular matrix 
composed mainly of water, Col II and proteoglycans. The collagen fibrils provide the 
cartilage with tensile strength and resistance to surface shear forces, while the aggrecan: 
proteoglycan complexes provide resistance to compressive loads 8, 9. Articular 
chondrocytes are insensitive to hypertrophy-stimulatory signals active in endochondral 
chondrocyte populations and do not undergo hypertrophic differentiation under normal 
circumstances. Instead, articular chondrocytes persist throughout life in a nominally pre-
hypertrophic state, characterized by the expression of Col II and aggrecan (Agg), with 
little or no Col X expression or ALP activity 10.  
The mechanism by which articular chondrocytes avoid hypertrophy is still not 
completely understood. There are several studies that indicate the transforming growth 
factor-β 11-13, bone morphogenetic proteins 14-16, and parathyroid hormone related peptide 
17-20 signaling pathways, mediated by lineage-specific transcriptional factors 21-29 are 
crucial to maintenance of articular cartilage and articular chondrocytic phenotype. 
In recent years, there has been an increasing recognition that epigenetics play a 
role in cell differentiation and phenotype commitment. Epigenetics refers to 
“mechanisms that initiate and maintain patterns of gene expression and gene function in a 
heritable manner without changing the sequence of the genome” 30. Epigenetics impact 
143 
 
gene regulation though DNA methylation, histone protein modifications and chromatin 
organization. DNA methyltransferases methylate cytidines at the CpG dinucleotide 
sequences. This modification can interfere with the recognition of binding sites by DNA 
binding proteins. Additionally, methyl-CpG binding proteins recruit histone deacetylases 
(HDACs), histone methyltransferases (HMTs) and chromatin-remodeling factors. These 
modifications condense chromatin structure, hiding potential binding sites for 
transcriptional activators and restricting occupancy. As a consequence, transcription is 
repressed. MicroRNAs are also involved in DNA methylation in Arabidopsis thaliana 31 
and might also be involved in regulating the histone deacetylase HDAC4 in murine 
developing cartilage 32. Recent findings suggest that at least 30% of genes are regulated 
by microRNAs; however, at this stage the epigenetic role of microRNA is predominantly 
indirect. 
Epigenetic processes are involved in regulation of germline-specific genes, tissue-
specific genes, imprinting, and aging 30, 33. In addition, experiments using inhibitors of the 
DNA methyltransferases have induced mouse embryo fibroblasts to differentiate into 
muscle, adipose tissue and chondrocytes 34-36, and to inhibit differentiation of 
spermatogonia into spermatocytes 37. These findings suggest that DNA methylation is 
involved in the regulation of gene expression during cell differentiation and lineage 
commitment 38-40.   
Epigenetic pathways also act in maintenance of the chondrocytic phenotype. The 
transcription factor Sox-9 is a master regulator of several chondro-specific genes 21-29. 
Tsuda and co-workers demonstrated that the histone acetyltransferase (HAT), CBP/p300, 
associates with Sox-9 to regulate transcription of the Col II gene in chondrocytes 41. p300 
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increases Sox-9 dependent transcription by increasing acetylation of histone amino tails 
in chromatinized DNA templates in vitro. In addition, trichostatin A, a histone 
deacetylase inhibitor, stimulates expression of Col II and aggrecan, and increased 
nucleosomal acetylation around the Sox-9 binding site in chondrocytes 42. Taken 
together, these results support a model whereby the gene-specific factor Sox-9 interacts 
with non-specific chromatin-remodeling factors to activate Col II transcription in 
chondrocytes. 
HDAC4 null mice exhibit premature chondrocyte hypertrophy and ossification, a 
phenotype similar to mice that overexpress RUNX-2 in chondrocytes. In addition, 
constitutive expression of HDAC4 mimics the phenotype seen in RUNX-2 knockout 
mice 43. RUNX-2 is a transcription factor necessary for hypertrophic differentiation of 
chondrocytes. In vitro studies showed that HDAC4 interacts with RUNX-2, inhibits 
RUNX-2 DNA-binding and decreases histone acetylation of the RUNX-2 promoter 43.  
Collectively, these data support a model in which HDAC4 negatively regulates 
chondrocyte differentiation by suppressing the activities of RUNX-2 with consequent 
inhibition of gene expression required for hypertrophy. In this model, HDAC4 is not 
acting in an epigenetic capacity, but is regulating the acetylation status of a non-genomic 
substrate. HDAC activity is also necessary to support collagen type II expression in 
articular chondrocytes, and permit re-differentiation of chondrocytes de-differentiated in 
monolayer 44. In this study, collagen type II expression was linked to suppression of Wnt-
5a expression by HDACs; again, a likely non-epigenetic activity.  
DNA methylation also influences the chondrocytic phenotype. Phenotypically 
stable, chick articular chondrocytes, cultured as monolayers and treated with the DNA 
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methyltransferase inhibitor, 5-azacytidine (5-aza), adopted a hypertrophic phenotype, 
expressing Col X, Indian hedgehog (Ihh), and ALP 45. Similarly, bovine fetal 
chondrocytes cultured as monolayers expressed hypertrophic markers in response to 5-
aza treatment.  Chondrocytes exposed to 5-aza for 48 hours decreased collagen type II 
expression and upregulated hypertrophic marker expression such as ALP, Col X, along 
with PTHrP and its receptor 46. In addition, human articular chondrocytes cultured in 
alginate beads and exposed to 5-aza undergo phenotypic changes that resemble 
hypertrophy, including increases in cell size and apoptotic death 47, consistent with 
transition from an articular to an endochondral phenotype.  
Although the results of the 5-aza/chondrocyte studies mentioned above provide 
persuasive evidence for a role for CpG methylation in the regulation of articular and 
endochondral lineages, these studies utilized incompletely committed cell populations or, 
with the exception of Ho et al, culture models that intrinsically compromise the 
differentiated phenotype of chondrocytes.  The objective of this study was to assess the 
phenotypic effects of 5-aza in healthy and fully committed articular and endochondral 
(growth plate) chondrocyte s isolated from the same donors, under culture conditions that 
support the differentiated chondrocytic phenotype, to determine whether 5-aza can induce 
spontaneous hypertrophy or increase hypertrophy-responsiveness in these distinct 
chondrocyte populations. Two questions were addressed. Firstly; does 5-aza 
administration directly stimulate expression of hypertrophic genes in articular and growth 
plate chondrocytes? Secondly, does 5-aza administration alter the phenotypic responses 
of articular and growth plate chondrocytes to exogenous BMP-2 administration?  
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METHODS  
 
Sample collection and cell isolation 
Articular cartilage was collected from the femorotibial joints of three young adult 
horses (3-5 years of age) with no clinical evidence of arthritic disease. In addition, equine 
articular and growth plate cartilages were collected from three neonatal horses, within the 
first week of life, euthanatized for reasons other than musculoskeletal disease. Within this 
age range, the growth plate cartilage plates of the major long bones are easily separable 
from the adjacent epiphyseal and metaphyseal bone fronts. Articular cartilage was 
excised from the femorotibial, scapulohumeral and humeroradial joints. The epiphyses 
and adjacent metaphyses of the humerii, femora, proximal tibia and distal radii were then 
sectioned longitudinally at 5-mm intervals, using an oscillating bone saw, to create full-
width slabs of the epiphyseal/growth plate/metaphyseal tissues. The growth plate 
cartilage was then separated from the adjacent bone by fracturing the chondro-osseous 
interface. 
The cartilage specimens were diced, washed in phosphate buffered saline (PBS) 
(HyClone, Logan, UT) and then transferred to 500-mL Erlenmeyer flasks containing 10 
mL/g of cartilage of Trypsin-EDTA (Gibco, BRL-Life Technologies, Grand Island, NY) 
supplemented with penicillin G sodium (200 units/mL) streptomycin (200 µg/mL) 
(Gibco), 2.5 µg/mL of amphotericin B (Cellgro, Mediatech, Inc, Herndon, VA). The 
flasks were placed in a C24 Shaking Incubator (New Brunswick Scientific, Edison, NJ) at 
180 rpm at 37oC for an hour. The pre-digestion solution was aspirated and the explants 
were rinsed with PBS, then resuspended in 10 mL per gram of tissue in 0.15% 
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collagenase II (Worthington Biochemical Corporation, Lakewood, NJ)  reconstituted in 
Opti-MEM supplemented with penicillin G sodium (200 units/mL) streptomycin (200 
µg/mL), 2.5µg/mL of amphotericin B and 2% of fetal bovine serum (Gemini Bio 
products, West Sacramento, CA) was added to the flask for the overnight digestion in the 
C24 Shaking Incubator at 180 rpm at 37°C.  
After the overnight digestion, the cell suspensions were filtered through a 40-
micron filter (Nalgene Company, Fisher Scientific, Pittsburgh, PA) into a 50-mL Falcon 
tube (Fisher Scientific). The flask and filter were rinsed with PBS to recover any residual 
cells.  After filtration, the cells were pelleted by centrifugation (Beckman Coulter, Inc., 
Fullerton, CA) for 10 minutes at 290 rcf. The supernatant was aspirated and the cell pellet 
was re-suspended in PBS and pelleted following the same protocol to assure removal of 
residual collagenase. The wash step was repeated several times for the growth plate 
chondrocytes due to the increased amount of debris and blood. Finally, the cells were 
resuspended in 10-20 mL of Opti-MEM for cell counting and viability assessment.  
 
Cell count and viability  
 The cell numbers were calculated using a hematocytometer (Fisher Scientific) and 
inverted light microscope (Fryer Co. Inc., Huntley, IL).  Two vials containing a 1:10 
dilution of the cell suspension and 10% Trypan blue dye (Gibco) were prepared.  The 
samples were well mixed and 10 µL were added to each side of the hematocytometer. 
Dead and live cells were counted in a total of 9 (1 mm2) squares in each side. The total 
number of cells in the cell suspension was obtained by the following formula:  
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# cells = # of cells counted/18 (# of 1 mm2 squares counted) x 10 (cell dilution) x 10 or 
20 (total volume of the cell suspension) x 104 
 
Culture conditions 
Three to four million chondrocytes were cultured as non-adherent aggregates in defined 
serum-free culture medium (Opti-MEM, Gibco) in six-well (10 cm2) hydrogel-coated, 
ultra low attachment culture plates (Corning Costar, Pittsburgh, PA).  The medium was 
supplemented with ascorbic acid (Sigma-Aldrich, St. Louis, MO) (50 µg/mL) and 
penicillin G sodium (100 units/mL) streptomycin (100 µg/mL).  Cultures were 
maintained at 37°C, in 95% air/ 5% CO2 in a humidified incubator (Fisher Scientific). 
After 24 hours, the chondrocytes were treated with 10 µM of 5-azacytidine (Sigma-
Aldrich) or maintained in basal medium (controls) for 4 days. On day 4, the 5-aza 
cultures were divided into two groups. The first group was treated continuously with 5-
aza for an additional six to eight days (aza cont). The second group was washed with 
medium to remove the 5-aza and allow recovery, and then maintained in control media 
for the remaining culture period (aza rec). The control cultures (Cx), aza cont and aza rec 
cultures were additionally maintained in the presence or absence of 100 ng BMP-2/mL, 
to stimulate hypertrophy. In some experiments, 100 ng thyroid hormone (T3)/ml was also 
administered to stimulate hypertrophic differentiation.  Chondrocyte aggregates were 
collected after 4 days of 5-aza exposure, and at the conclusion of the experiments, and 
were snap frozen in liquid nitrogen and stored at -80°C for further processing. 
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RNA isolation 
 Total RNA was isolated from the chondrocyte aggregates using the phenol-based 
dissociation agent, TRIzol® (Invitrogen Corporation, Carlsbad, CA).  One milliliter of 
TRIzol® was added to each frozen aggregate pellet and the sample was immediately 
homogenized using an Ultra-Turrax T25 homogeneizer (Janke & Kunkel, IKA-
Labortechnik, Staufen, Germany) for 30 seconds.  The samples were then centrifuged in a 
refrigerated centrifuge 5810 R (Eppendorf) at 453 rcf for 10 minutes to precipitate the 
insoluble debris.  The TRIzol® supernatants were transferred to a 1.5-mL microcentrifuge 
tube (Eppendorf) and 200 µL of chloroform per milliliter of TRIzol® was added to 
separate the aqueous and organic phases of the lysate.  After vortexing, the tubes were 
centrifuged in a refrigerated centrifuge (Centrifuge 5415 R, Eppendorf) at 16,100 rcf for 
30 minutes at 4°C. The upper aqueous phase (approximately 400 µL) was removed and 
placed in a new 1.5-mL microcentrifuge tube.  During this step, great care was taken to 
leave the insoluble material at the interface intact. This interface material is comprised of 
insoluble proteins, lipids, DNA and, with chondrocyte cultures, large amounts of 
proteoglycans. To maximize RNA yields, the remaining aqueous volume and a small 
amount of the adjacent interface was then transferred to a 0.5-mL microcentrifuge tube 
(Fisher). These smaller tubes were then centrifuged at 16,100 rcf and an additional 100-
200 µL of aqueous phase was transferred to the 1.5-mL microcentrifuge tubes. 
The RNA was precipitated from the aqueous solution by addition of 250 µL of 
isopropanol and 250 µL of 1.2 M sodium chloride/0.8M sodium citrate. This high-salt 
precipitation protocol minimizes co-precipitation of sulfated proteoglycans. The 
microcentrifuge tubes were stored overnight at -20°C to facilitate RNA precipitation.  
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The samples were then centrifuged at 16,100 for 30 minutes at 4°C to pellet the RNA.  
The pellet was washed with 500 µL of 70% ethanol to reduce the salt content of the 
pellet, and allowed to air dry for 10 minutes.  The pellet was dissolved in diethyl 
pyrocarbonate (DEPC)-treated water.  A 1:40 aliquot of each sample was used to quantify 
the nucleic acid concentration spectrophotometrically (SmartSpecTM 3000, Bio-Rad, 
Hercules, CA), using optic density (OD) values at 260 and 320 nM. The concentration of 
total RNA was calculated as follow:  
RNA in µg/µL= OD at 260 nM – OD at 320 nM x 40 (dilution factor) x 40 (coefficient) 
                           1000 
 
Northern blot analyses 
Four micrograms of total RNA were precipitated and loaded in a 1% 
agarose/formaldehyde gel to allow transcript size separation by electrophoresis in MOPS 
buffer as previously described 48. The electrophoresed RNA was transferred from the gel 
onto nylon membranes (GE Infrastructure, Minnetonka, MN) by overnight capillary 
transfer using a high-salt (10X SSC) transfer solution. The transferred RNAs were 
immobilized to the nylon substrate by UV irradiation crosslinking (Spectrolinker XL-
1000 UV crosslinker, Spectronic Corporation, Westbury, NY). 
For Northern blot hybridization, membranes were re-hydrated, rinsed in 5xSSPE 
and then pre-hybridized at 65°C in a rotating hybridization oven for 1-2 hours in pre-
hybridization solution (5X SSPE, 5 X Denhardt’s solution (Eppendorf), 0.25% SDS 
(Fisher Scientific), 10% dextran sulfate (Fisher Scientific)) and 150 µg/mL denatured 
salmon sperm DNA (Invitrogen). Isotopic probes were prepared by random-primed 
labeling, using a commercial labeling kit (Prime-it® II, Stratagene, Cedar Creek, TX) and 
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32P-dCTP (Amersham, Piscataway, NJ). The probes were purified using G-50 Sephadex 
spin columns (Boehringer-Mannheim, Indianapolis, IN), denatured and then added to 
hybridization tubes containing the pre-hybridized membranes.  
After overnight hybridization, the membranes were rinsed in 2X SSPE, 0.5% 
SDS. Sequential washes were done until background activity was minimal, as assessed by 
a handheld Geiger counter GSM-110 (Wm. B. Johnson & Associates, Inc., Fairlea, WV). 
The membranes were wrapped in Saran plastic (Jonhson  & Son Inc., Racine, WI) and 
exposed overnight to a phosphor screen (Packard Instrument Comp, Inc., Meridan, CT) 
for quantitative analyses of signal intensity with Cyclone Storage Phosphoscreen 
(Packard). Finally, the membranes were exposed to autoradiograph film (Kodak Bio-Max 
MS Film, Carestream Health, Inc., Rochester, NY) for “hardcopy” recording of 
membrane activity. Radiograph cassettes were stored overnight at –80°C.  Dr Dean 
Richardson generously provided the equine collagen type X cDNA used as a probe 
template for these experiments. The EF1α cDNA used for Northern blot probe synthesis 
was generated by the primers listed in Table 7.  
 
Reverse transcription  
First strand cDNA was synthesized by reverse transcription using First Strand 
cDNA Superscript II (Invitrogen) and Oligo dT as per manufacturer’s instructions. 
Briefly, one microgram of total RNA was brought up to 10 µL and then combined with 1 
µL of oligo (dT) (0.5µg/µL) and 1 µL of 10 mM dNTPs. The sample was incubated in a 
65°C water bath for 5 minutes and then placed on ice for 1 minute to denature the RNA 
and allow binding of the oligonucleotides.  The following reagents were added: 2 µL 10x 
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First Strand Buffer, 2 µL 0.1M DTT, 2 µL 50 mM MgCl2 and 1 µL RNase out. After a 
gentle mix and brief centrifugation, the sample was incubated at 42°C water bath for 2 
minutes, 1 µL (50 units) of SuperScript II Reverse Transcriptase was added. The sample 
was then incubated at 42°C for 50 minutes. The reaction was stopped by placing the 
sample in a 70°C water bath for 15 minutes.  The RT reactions were diluted (1:10 ratio) 
with water and stored at -20°C until further use. 
 
Quantitative polymerase chain reaction (qPCR) 
 Quantitative PCR (qPCR) was used to compare Col X and ALP gene expression 
profiles of articular and growth plate chondrocytes samples. The PCR reactions were 
carried out in a final volume of 25 µL.  The 2x SYBR Green Supermix (Bio-Rad 
Laboratories, Hercules, CA) was used for these reactions. This reagent contains  100 nM 
KCl, 40 mM Tris-HCl, 0.4 mM of each dNTP, 50 units/mL of Taq polymerase, 6 mM 
MgCl2, and 20 nM SYBR Green I.  The SYBR Green Supermix (12.5 µL) was added to 1 
µL of the sense (10 pMol) and antisense primers.  Autoclaved distilled water (5.5 µL) 
and 5 µL of cDNA template were also added.  PCR conditions were: initial denaturation 
step at 95°C for 3 minutes, followed by 45 cycles of denaturation at 95°C for 10s, 
annealing temperature of 62°C for 30s and polymerase extension at 72°C for 20s. The 
samples were denatured at 95°C for 1 min before starting the melting curve protocol that 
consisted of decreasing the temperature at 55°C for 1 minute followed by increments of 
0.5°C every 10 s till 95°C was reached.  The primers are listed in Table 7. The primer 
combinations used in these experiments were designed for annealing at 60-62°C, 
however optimal annealing temperatures were determined by temperature gradient 
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analyses spanning 54-64°C. The specificity of the PCR products was monitored by 
melting curve analyses, PCR fragment cloning and sequencing.  Graphs showing the 
fluorescence intensity were plotted for each cycle.  Quantitative results were accessed 
using the cycle threshold determined to represent the onset of the linear phase of 
amplification, as calculated by the thermal iCycler software (Bio-Rad). To exclude 
contamination, water was used as negative control for each on the reactions instead of 
cDNA. PCR amplification of each sample was run in duplicate and qPCR data was 
normalized by the elongation factor-1 alpha (EF1α) expression.  
 
Statistical analyses  
 Differences between Col X and ALP mRNA levels after 12 days in culture (and 
after 8 days of control or BMP-2 exposure) were assessed by one-way ANOVA. Were 
significant differences were identified (p <0.05), Bonferoni’s post hoc tests were used to 
identify specific effects of 5-aza treatment and BMP-2 administration.  
 
RESULTS 
Phenotypic effects of 5-aza on adult articular chondrocytes 
Treatment of fully differentiated articular chondrocytes from adult horses with 5-
azacytidine did not stimulate phenotypic change suggestive of hypertrophic 
differentiation.  As seen in Figure 20A, initial treatment with 5-aza for four days did not 
induce collagen type X expression and Col X transcripts were undetectable in both 
control and aza-treated samples after 6 days treatment with BMP-2 or thyroid hormone. 
Both the agents are potent stimulators of hypertrophy in competent chondrocyte 
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populations. In a similar experiment that assayed persistent and transient (4 day) 5-aza 
treatment in conjunction with BMP-2 administration, neither Col X nor ALP expression 
was significantly affected (Figure 20B). The threshold cycles for these qPCR outcomes 
were consistently above 30 cycles; approximately 10 cycles above threshold for Col X 
and ALP expression in endochondral-competent chondrocyte populations. 
 
Phenotypic effects of 5-aza on neonatal chondrocytes 
Articular and growth plate chondrocytes were collected from three equine 
neonates, within the first few days of life. In fact, the third foal in this study was obtained 
through a dystocia-related death of the mare. As a consequence, this foal had not been 
ambulatory prior to the tissue collections. To ensure that the articular chondrocytes 
collected from these foals were phenotypically consistent, the behavior of these cell 
populations under control culture conditions was assessed. The results of these analyses 
using cells from the third donor foal are shown in Figure 21. The data from both articular 
and growth plate chondrocytes were normalized to EF1α mRNA levels to allow direct 
comparison. As is clearly evident, neither chondrocyte type underwent spontaneous 
differentiation in basal medium. BMP-2 administration induced substantial collagen type 
X and ALP up-regulation in growth plate chondrocytes after 8 days, whereas articular 
chondrocytes expressed no evidence of hypertrophic differentiation. On the basis of these 
findings, the effects of 5-aza on articular and growth plate chondrocytes were assessed 
after 8 days of BMP-2 administration.  
 In control cultures, articular chondrocyte Col X expression was initially 
detectable at relatively low levels (threshold above 24 cycles) and expression fell during 
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time in culture. Initial exposure to 5-aza for four days did not significantly alter Col X 
levels. Neither removal of 5-aza from the culture medium after four days, nor persistent 
5-aza for the subsequent 8 days of the experiments affected Col X expression.  Finally, 
co-treatment with BMP-2 did not up-regulate Col X expression. Representative data from 
chondrocytes isolated from the second equine donor are presented in Figure 22 (upper 
panel).   
 Initial ALP expression in articular chondrocytes was consistently low (threshold 
over 32 cycles) and basal ALP expression did not change with time in culture. 5-aza 
treatment, whether transient or persistent, did not increase expression of ALP expression, 
in comparison to control levels. Representative data from chondrocytes isolated from the 
second equine donor are presented in Figure 22 (lower panel). BMP-2 administration did 
increase ALP expression of control cultures, albeit with considerable variability between 
the three donors (597-, 2.25- and 38.7-fold increases over control values). The qPCR 
cycle threshold cycles in these analyses were consistently at or above 30; arguably below 
levels of biological relevance.  In contrast, both collagen type II and aggrecan were 
highly expressed in all samples (data not shown).  
In growth plate chondrocyte control cultures, Col X expression fell over time. 5-
aza treatment, whether transient or persistent, did not induce expression of Col X. As 
expected, Col X was up-regulated by BMP-2 treatment. Persistent 5-aza administration 
inhibited growth plate chondrocyte responses to BMP-2. In contrast, transient exposure 
significantly increased Col X induction by BMP-2. Representative data from 
chondrocytes isolated from the second donor foal is shown in Figure 23 (upper panel). 
Transient 5-aza administration increased Col X expression in response to BMP-2 in all 
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three experiments; however, this effect was variable, ranging from 1.5- to 16-fold 
increases.   
Low levels of ALP expression were maintained throughout the experiments. 5-aza 
treatment, by itself, did not induce expression of ALP. Persistent 5-aza administration 
inhibited any response to BMP-2, as with Col X expression (above). Transient 5-aza 
expression resulted in modest but not significant increases in ALP expression in response 
to BMP-2 administration. Representative data from chondrocytes isolated from the 
second donor foal is shown in Figure 23 (lower panel). As with the articular cartilage 
samples, collagen type II and aggrecan were consistently expressed in all experiments 
(data not shown). 
The extent to which 5-aza administration induced a phenotypic transition towards 
a hypertrophic/endochondral chondrocyte type is graphically represented in Figure 24, 
where expression of the phenotype-specific genes in both cell types has been normalized 
to EF1α. In comparison to the Col X and ALP expression levels induced by BMP-2 in 
growth plate chondrocytes, expression of these hypertrophic markers by articular 
chondrocytes was consistently negligible. The results of this study do not indicate that 5-
aza is able to induce hypertrophic transformation in articular chondrocytes, although 5-
aza did variably increase the responsiveness to growth plate chondrocytes to BMP-2 
administration. 
 
DISCUSSION 
Epigenetics refers to “mechanisms that initiate and maintain patterns of gene 
expression and gene function in a heritable manner without changing the sequence of the 
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genome” 30. Epigenetics impact gene regulation though DNA methylation, histone 
protein modifications and chromatin organization. Several studies have demonstrated the 
importance of epigenetics in stem cell differentiation and lineage commitment. For 
example, several germline-specific genes are methylated in fibroblasts but not in sperm 
33, suggesting that DNA methylation is involved in repression of germ-line specific genes 
in somatic cells, and participates in the epigenetic regulation of gene expression during 
cell differentiation 38-40. Moreover, genome-wide screens have provided information on 
differential methylation in different types of tissues 39, 49-52.  
The DNA methyltransferase inhibitors are derivates of 5-azacytidine (5-aza). 5-
aza is a cytidine analog modified at position 5 that cannot be methylated. It was originally 
synthesized by Piskala and Sorm in 1964 with the objective to treat acute myelogenous 
leukemia 53.  More recently, 5-aza and several other cytidine analogues, such as 5-aza-2-
deoxicytidine (5-aza-CdR), zebularine, and decitabine, among others, have been used to 
treat several neoplastic diseases 54, 55. DNA methyltransferase inhibitors have been used 
to experimentally address the effects of DNA methylation on cellular differentiation and 
phenotypic stability. For instance, DNA methyltransferase inhibitors induce mouse 
embryonic fibroblasts to differentiate into muscle, adipose tissue and chondrocytes 34-36. 
In addition, 5-aza-deoxycytidine (5-aza-CdR), prevents differentiation of spermatogonia 
into spermatocytes in mouse 37, which suggests that DNA methylation is important for 
terminal differentiation of spermatocytes. On the other hand, the treatment of articular 
chondrocytes with DNA methyltransferase inhibitor alleviates molecular constraints that 
prevent these cells from achieving terminal maturation 45. It should be noted that, in many 
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of these differentiation-focused studies, the specific mode of 5-aza action was not 
identified and alterations in DNA methylation were not directly addressed.  
In this study, we investigated whether 5-aza could induce expression of 
hypertrophic genes in equine articular and growth plate chondrocytes, and whether 5-aza 
administration could affect the phenotypic responses of equine articular and growth plate 
chondrocytes to exogenous BMP-2 administration.  
All cells presented high levels of expression of the chondrocyte-specific genes 
aggrecan and collagen type II. This suggests that the chondrocytic phenotype was 
maintained throughout the experiments. This is not surprising since the culture system 
used is known to maintain the chondrocytic phenotype 16, 56. Articular chondrocytes 
expressed very little Col X or ALP mRNAs. Further, articular chondrocytes did not 
upregulate either of these hypertrophic genes in response to BMP-2. Moreover, 5-aza 
treatment did not induce expression of the hypertrophic genes or altered the articular 
chondrocytes’ response to the hypertrophic effects of BMP-2. It is possible that the 
disparity between our results and Zuscik et al’s findings could be explained by the 
difference in cell culture conditions. Zuscik et al cultured chondrocytes as monolayers 
and in the presence of serum. These culture conditions induce phenotypic 
dedifferentiation, markedly altering cell shape and down-regulating expression of 
chondrocyte-specific genes such as collagen type II and aggrecan 16, 56. It is also known 
that serum contains several growth factors and also interfere with the phenotypic stability 
of chondrocytes. These model-linked factors could have increased the cells’ ability to 
respond to 5-aza and undergo hypertrophy. The study by Zuscik et al used chondrocytes 
isolated from the articular and epiphyseal regions of chick tibiae. Given that skeletal 
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development and growth in avian species differs considerably from mammalian growth 
in several respects, the difference in 5-aza responses may reflect differing phenotypic 
characteristics of immature avian and mammalian ‘articular’ cell populations; Zuscik et 
al’s avian articular cells behaved very similarly to the equine growth plate cells. It is also 
possible that the non-adherent aggregate culture model used in our study supported 
insufficient proliferation to permit 5-aza genomic incorporation, although previous 
studies have established that chondrocytes maintained in aggregate cultures undergo at 
least one population doubling during the first 3-4 days in culture. Generally, only 5% of 
cytidines are substituted by 5-aza, but this degree of substitution is sufficient to induce a 
global decrease in genomic DNA methylation (80-85%), due to consequent covalent 
binding of Dnmt1 57, 58 which effectively sequesters the enzyme and leads to a global 
reduction in genomic methylation 59, 60.   
As reported by Ho et al 2006, human articular chondrocytes cultured in alginate 
beads undergo phenotypic changes that resemble hypertrophy, following 5-aza treatment, 
with up-regulation of Col X and ALP expression and down-regulation of collagen type II 
47. These results also contradict the outcomes of the current study; however the up-
regulation of Col X and ALP after 20 days in culture in Ho et al’s study, two-fold and 10-
fold respectively, were modest when expression levels of bona fide endochondral 
chondrocytes are considered and are substantially less than the alteration in hypertrophic 
marker expression seen in osteoarthritic articular chondrocytes (see Chapter 4). From a 
quantitative perspective, it is difficult to accept that conclusions of Ho et al that 5-aza 
administration resulted in hypertrophic differentiation of human articular chondrocytes. 
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Equine growth plate chondrocytes were used to determine whether 5-aza 
augments the hypertrophic response of endochondral chondrocytes. In control cultures 
Col X expression decreased over time while ALP expression was maintained at low 
expression levels throughout the experiment.  As expected, both Col X and ALP were up-
regulated by BMP-2 treatment. Similarly to articular chondrocytes, 5-aza treatment, by 
itself, did not increase expression of the hypertrophic genes Col X or ALP. However, pre-
treatment with 5-aza increased Col X up-regulation in response to BMP-2, compared to 
control samples. These results are consistent with the findings of Cheung et al 2001. In 
Cheung et al’s study, fetal bovine epiphyseal (endochondral) chondrocytes treated with 
5-aza up-regulated hypertrophic gene markers and increased cell volume 46. In a 
subsequent study, it was also shown that 5-aza induced chondrocyte apoptosis, another 
feature of terminal chondrocyte differentiation 61. Collectively, these results suggest that 
5-aza administration does increase the capacity of endochondral chondrocyte populations 
to undergo hypertrophic differentiation with appropriate stimulation.  
Accepting this conclusion, no data are available to support a direct link between 
changes in genomic methylation status and consequent phenotypic alterations. 5-aza also 
influences cellular activity through induction of the DNA damage response, which leads 
to p53 activation, p21Waf1/Cip1 up-regulation and cell cycle arrest 62. This mechanism 
could explain the increased chondrocyte apoptosis observed in Ho’s study, for instance. 
Given that growth arrest is an integral feature of hypertrophic differentiation, the 
observed phenotypic effects of 5-aza on endochondral chondrocytes could relate to cell 
cycle regulation, as opposed to any epigenetic mechanisms. 
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In conclusion, the outcome of this study does not support the contention that 
interference with DNA methylation “trans-differentiates” articular chondrocyte 
populations into the endochondral lineage. In fact, fully differentiated articular 
chondrocytes were remarkably resistant to phenotypic effects of 5-aza. In contrast, 
transient 5-aza administration did augment the hypertrophic response of growth plate 
chondrocytes to BMP-2, suggesting that changes in genomic methylation profiles 
influence the progression of endochondral chondrocytes through hypertrophic 
differentiation.  
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FIGURES AND TABLES 
Table 7. Primers utilized in the qPCR reactions 
Gene  
size 
Sense primer 
Antisense primer 
Annealing 
temperature  
Collagen type II  5’AGCAGGAATTTGGTGTGGAC (4297) 62°C 
(223 bp) 5’TCTGCCCAGTTCAGGTCTCT (4520)  
Collagen type X 5’TGCCAACCAGGGTGTAACAG (1605) 62°C 
(244 bp) 5’ACATTACTGGGGTGCCGTTC (1840)  
ALP  5’TGGGGTGAAGGCTAATGAGG (357) 62°C 
(221 bp) 5’GGCATCTCGTTGTCCGAGTA (578)  
EF1α  5’CCCGGACACAGAGACTTCAT (368) 62°C 
(328 bp) 5’AGCATGTTGTCACCATTCCA (696)  
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Figure 20. Response of adult articular chondrocytes to 5-azacytidine. A. Northern blot 
of Col X mRNA expression following 5-aza administration and subsequent treatment 
with thyroid hormone (T3) of BMP-2. Growth plate RNA was used as the positive 
control (+). B. qPCR analyses of Col X and ALP mRNA expression in response to 
BMP-2 under ‘control’ conditions, in the presence of ‘5-aza’, and in ‘recovery’ cultures, 
where 5-aza was removed after 4 days. Y axes indicate fold changes in expression. 
There were no significant responses to BMP-2 following persistent or transient 5-aza 
administration. 
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Figure 21. Phenotypic distinctions between articular and growth plate chondrocytes 
isolated from equine neonates. qPCR analyses of Col X (upper panel) and ALP (lower 
panel) mRNA expression in the presence or absence of 100 ng BMP-2/ml. Responses by 
articular chondrocytes were negligible, whereas growth plate chondrocytes robustly 
increased both Col X and ALP expression in response to BMP-2 administration.  
 
169 
 
 
 
Figure 22. Response of neonatal articular chondrocytes, subject to continuous (aza cont) 
or transient (aza rec) 5-aza treatment, to BMP-2 administration. Expression of Col X and 
ALP mRNAs was assessed by qPCR.  
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Figure 23. Response of neonatal growth plate chondrocytes, subject to continuous (aza 
cont) or transient (aza rec) 5-aza treatment, to BMP-2 administration. Expression of Col 
X and ALP mRNAs was assessed by qPCR. Asterisks indicate a significant response to 
BMP-2 over the appropriate control sample. # indicate a significant effect of 5-aza over 
the appropriate control sample (ANOVA; p< 0.05). Note the Y axis break in the ALP 
data.  
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Figure 24. Comparative responses of neonatal articular and growth plate chondrocytes, 
subject to continuous (aza cont) or transient (aza rec) 5-aza treatment, to BMP-2 
administration. Expression of Col X and ALP mRNAs was assessed by qPCR. There was 
an approximately 400-fold difference between the levels of collagen type X mRNA 
expression in articular and growth plate chondrocytes (isolated from the same donor; 
upper panel) while ALP expression was over 30-fold higher in growth plate 
chondrocytes. Asterisks indicate a significant response to BMP-2 over the appropriate 
control sample. # indicate a significant effect of 5-aza over the appropriate control sample 
(ANOVA; p< 0.05)  
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CHAPTER 6: CONCLUSIONS 
 
 The research presented in this thesis addressed the actions of 5-azacytidine on the 
chondrocytic phenotype in two contexts. The first series of experiments, presented in 
Chapter 3, focused on the suppression of collagen type II expression in osteoarthritic 
articular chondrocytes, and the responses of these cells to 5-aza administration. The 
second research focus addressed the phenotypic transitions that develop in osteoarthritic 
articular chondrocytes (Chapter 4) and the impact of 5-azacytidine on the phenotypic 
distinctions between articular and endochondral (growth plate) chondrocyte populations 
(Chapter 5). 
The experiments addressing regulation of collagen type II expression 
demonstrated that 5-aza significantly increased collagen type II mRNA levels, and 
concurrently up-regulated a number of other critical matrix genes; however, a 
comprehensive analysis of the methylation status of the collagen type II promoter and 
enhancer CpG island sequences demonstrated comprehensively that the mechanism of 5-
aza’s effect on collagen type II expression was not direct CpG de-methylation in these 
regions. On the contrary, comparative analyses of control and 5-aza treated specimens 
indicated that 5-aza was not influencing the existing CpG methylation status at all. 
Adenoviral over-expression of p53 and p21, simulating the DNA damage repair response, 
did not alter collagen type II expression, suggesting that this potential mechanism was 
also not responsible for 5-aza’s effects. Candidate gene screening identified TGF-β3 as a 
potential effector of 5-aza’s activity, but additional experiments are necessary to 
determine whether TGF-β3 up-regulation is responsible for 5-aza’s effect on 
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chondrocytes. Genome-wide methyl CpG screening of normal and osteoarthritic articular 
chondrocyte populations will provide unbiased data on the DNA methylation changes 
that occur in arthritis and could identify differentially regulated and expressed genes that 
contribute to disease progression. In these analyses, the issue of ‘age’ also needs to be 
addressed, since stochastic genomic methylation undoubtedly accumulates during the 
several decades required for the clinical development of osteoarthritis.  
Although high throughput ChIP-chip and ChIP-SEQ technologies have 
revolutionized the capacity and resolution of epigenomic analyses, much of the existing 
data sets have been generated from cell lines and from a very limited number of normal 
tissues. There is a growing appreciation that the epigenetic profiles of cell lines do not 
reflect those of the parental tissues. This is particularly pertinent to the field of articular 
chondrocyte biology, since no phenotypically robust cell lines are available. In addition, 
it is now obvious that CpG methylation acts in concert with histone modifications and, in 
all likelihood, microRNAs to regulate cellular transcriptional activity.  
In future experiments, primary cell specimens from multiple donors, representing 
both healthy and diseased states, should be used to generate a comprehensive and 
informative data base of normal and pathological epigenomes, encompassing a 
comprehensive panel of epigenetic marks, in representative tissues. Again, in the context 
of chondrocyte biology, this would be extremely challenging, since acquiring healthy 
articular cartilage from younger individuals (less than 30 years of age) is difficult. 
Appropriate non-rodent model species will need to be identified and validated to enable 
the development of a comprehensive cartilage epigenomic data base that can then be used 
to analyze and interpret human data sets.  
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 The second research focus addressed the effects of 5-aza on the articular and 
endochondral chondrocytic phenotypes. This interest was prompted by several published 
studies that implicated 5-aza and, by extension, DNA methylation in the regulation of 
chondrocyte lineage commitment. Our own studies did not support the conclusion 
reached by other researchers that 5-aza is able to drive hypertrophic differentiation of 
articular chondrocytes, but growth plate differentiation was increased by transient 5-aza 
administration. As with the referenced published studies, the specific role of CpG 
methylation in this process was not determined. Ongoing research should focus on 
identifying the cellular mechanism(s) that mediate 5-aza’s effects on chondrocyte 
hypertrophy. Given the critical influence cell cycle arrest has on the phenotypic transition 
into the hypertrophic phase of differentiation, the up-regulation of p53 and p21 by 5-aza 
is an obvious avenue for future investigation.  
 Accepting that the mechanisms of action that mediate 5-aza’s effects on 
osteoarthritic and endochondral chondrocytes are currently uncertain, there are clear 
potential therapeutic applications for epigenetic modifying agents in arthritis and in 
endochondral bone formation. Several epigenetic agents have already been advocated for 
the suppression of catabolic enzymes that degrade cartilage matrix and our own data 
suggest that DNA methylation inhibitors could also support chondrocyte anabolic 
activities in the face of arthritic pathology.    
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